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ABSTRACT 
 
Clinicians lack appropriate non-invasive methods to be able to predict, diagnose, and 
reduce the risk of rejection in the years following kidney transplantation.  Protocol 
biopsies and monitoring of serum creatinine levels are the most common methods of 
monitoring graft function after transplant; however, they have several negative aspects.  
Use of traditional factors regarding donors and recipients such as Human Leukocyte 
Antigen (HLA) DNA typing, pre-transplant anti-HLA antibody levels, and basic 
demographics (age, ethnicity/race, gender), has proved inadequate for post-transplant 
graft monitoring past the first few years. We propose that by utilizing immunologic 
factors available to clinicians across the United States, development of a non-invasive 
model for predicting renal graft outcome will provide a useful tool for post-transplant 
patient monitoring.  We advocate an expanded model which incorporates both the 
traditional factors, as well as new factors, which have shown promise in predicting 
kidney outcome and are widely available for testing using commercial kits. These 
additional factors include major histocompatibility complex class I chain-related gene A 
(MICA) typing of donor and recipient, degree of matching for killer cell immunoglobulin-
like receptors (KIRs) between donor and recipient, detection of MICA antibodies, and 
soluble CD30 level (sCD30).  This proposed graft-function prediction model is the first to 
include all of these factors. 
Using multi-center data from adult recipients of standard-criteria deceased-donor (SCD) 
kidneys, we were able to construct models, containing the traditional factors only, for 
prediction of outcome at 1 year and 3 years post-transplant.  Using single-center data 
from adult recipients of standard-criteria deceased-donor kidneys, we developed 
comparison models containing traditional factors only, as well as, expanded models 
containing the new suggested variables for prediction of outcome post-transplant.  
These additional variables, when incorporated into the expanded models provided 
greater positive predictive values, greater negative predictive values, and lower false 
negative rates for graft outcome at 1 year and at 3 years post-transplant than the 
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models utilizing traditional factors only.  Our results indicate that evaluation of sCD30, 
MICA and KIR as part of routine protocol testing, is helpful to clinicians for predicting 
risk of kidney graft rejection. 
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CHAPTER I:  INTRODUCTION 
 
The current need for donated human organs for transplantation greatly exceeds the 
available supply.  This unfortunate reality drives both legislation and research focused 
on finding a solution.  Despite efforts to increase access to kidney transplantation, 
thousands of patients remain on waiting lists around the United States.  According to 
the 2009 Organ Procurement and Transplantation Network (OPTN) and the Scientific 
Registry of Transplant Recipients (SRTR) Annual Report, the total number of 
candidates on the wait-list at the end of the year for a kidney transplant has risen by 
86% in the last ten years, from 43,632 (1999) to 80,972 (2008).[1]  Laws passed to 
regulate transplantable organs and to improve the national system, both ethically and 
medically, aim to provide equitable access for kidney transplant candidates to deceased 
donor kidneys and improve the outcomes of these transplants.  As a result of these laws 
and regulations, several utility-based kidney allocation systems have been proposed 
which include various concepts such as Life Years From Transplant (LYFT) as a 
measure of transplant utility, Donor Profile Index (DPI) as a measure of donor quality, 
dialysis time as a measure of equity, and the Kidney Allocation Score (KAS) as an 
attempt to balance equity and utility.  However, these measures have not assisted the 
transplant community in solving the original problem:  available kidneys are a scarce 
resource.   
 
Available Organs/ Deceased Donors 
 While the wait-list continues to grow, the lack of available organs is proving difficult to 
overcome.  In 2008, there were only 10,101 kidney transplants from deceased donors 
(a +0.2% change from 2007) and 5,966 kidney transplants from living donors (-1.2% 
change from 2007).[1]  To put this in perspective, one must consider that if no new 
candidates were added to the wait-list and that approximately 16,000 kidneys become 
available in a year’s time (based on 2008 data), then it would take just over 5 years to 
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transplant all the candidates that existed on the wait-list in 2008.  Of course, new 
patients will continue to be added to the list and the gap between candidates on the list 
and number of transplants will continue to widen, just as it has over the last decade. 
There are several potential reasons for the shortage of organs.   
• Perhaps the most common reason is that people are hesitant to donate organs.  
Often people are fearful that if they sign an organ donor card then emergency 
medical services (EMS) will not “try as hard”.  They envision a medical technician 
or emergency room doctor throwing their organs into a cooler and rushing off to a 
waiting helicopter.  Organs are not collected roadside or stolen from potential 
donors lying in a bathtub of ice.  These irrational fears are caused by works of 
fiction and exacerbated by circulating urban legends.   
• Physicians and nurses may not ask family members whether they would consent 
to donating organs when their loved one dies.   
• Some caregivers, especially in rural areas, may not know how to contact an 
organ procurement organization (OPO).   
• In other cases, the deceased's wishes to donate his or her organs may not be 
known by those in the position to act on those wishes. 
• Family members may object to the procurement of organs from their deceased 
loved one, regardless of the deceased's wishes to the contrary.   
If the pool of available organs from deceased donors is not expanded, then other 
sources must be explored.  Current research is focused on two main goals:  Increasing 
the availability of organs (e.g. xenotransplantation, social programs) or improving long-
term survival rates of transplanted organs.  Currently, the one year, unadjusted, national 
kidney graft survival rate is 91.0% for deceased donors (DD) and is 80.1% for deceased 
donor kidney allografts at three years.[1]  Despite more powerful immunosuppressive 
drugs, chronic rejection continues to be a problem as the five and ten year graft survival 
rates drastically drop to 69.3% and 43.3% respectively.[1]  The following sections 
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provide an overview of contemporary approaches for increasing the number of available 
kidney allografts and improving graft survival.  
 
Available Organs/ Living Donors 
One of the most successful strategies to reduce waiting time and improve post-
transplant outcome is utilization of available living donor (LD) kidneys for 
transplantation.  Kidneys from LDs have several advantages over their DD counterparts, 
including reduced waiting times, shorter and less expensive hospital stays, greater 
opportunity for pre-emptive transplantation, and improved post-transplant outcome. 
[2,3,4]  Unfortunately, there has been a steady decrease in the use of LD kidney 
transplantation since 2004.  There are various factors, which could be responsible for 
this decline.   
• Economy--Changes in economic factors may increase reluctance to donate.  If a 
donor is not financially sound, adequately covered by insurance, has a fastidious 
employer, or is unemployed, they might not feel secure in electing to undergo a 
non-emergency surgery.   
• Older recipient population--The recipient population as it ages may have a more 
limited number of potential donors.  As the potential transplant candidate ages, 
so does their friends and family.  It is often more difficult for a 65 year old to 
obtain a LD than it is a 15 year old.   
• Decline in emphasis on recruitment.   
• Changes in donor/ recipient relationships--There has been a shift in the 
relationship of living donors and their recipients since 1999, which may be 
partially attributed to improved access to deceased donor kidneys for pediatric 
patients.  The most common relationships in 1999 were full sibling (35%), 
followed by parent (17%) and offspring (16%).[1]  However, in 2008 unrelated, 
non-spousal relationships such as friends, in-laws, or anonymous donors were 
4 
 
most common (26%), followed by full sibling (24%) and offspring (17%).[1]  
Parents only accounted for 10 percent of living kidney donors in 2008.   
o Part of this increase in unrelated donors may be a result of the emergence 
of kidney chains in the last few years.  Kidney chains are a product of 
kidney paired donation (KPD) programs, where two or more incompatible 
pairs exchange donors such that compatible transplants result.[5,6,7]   
o These multiple links of recipient-donor pairs may span across the country, 
through several transplant centers.  This has been made possible by 
mathematical optimization[8] and by replacing donor travel with organ 
transport.[9,10]   
Efforts must continue to increase the feasibility of kidney transplantation by LD.  The 
transplant community continues to focus on strategies to improve access to living 
donation for recipients of all races, ethnicities, and socioeconomic status.[11]  Areas of 
current interest include transplantation across immunological incompatibility (e.g. 
positive-crossmatch (posXM) desensitization),[12,13]  ABO incompatible (ABOi) 
transplantation,[14,15,16,17] use of laparoscopic donor nephrectomy to reduce donor 
recovery time, and a development of a national program offering economic support to 
donors. 
 
Immunosuppressant Drugs 
With limited donor populations, the transplant community is forced to explore alternate 
means of improving both availability and usage of kidneys.  The long-term survival rate 
of transplanted organs desperately needs to be improved.  The survival rate for a kidney 
transplant drastically drops after 5 years.  While immunosuppressive drugs have 
improved over the last decade, their role in transplant success still comes with 
drawbacks.  The drugs used to maintain allograft survival are not specific for the graft; 
they broadly suppress the immune system.  While these drugs have allowed for 
excellent short term graft survival, they do not seem to have much effect on long-term 
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survival and often come with serious complications.  Current immunosuppressive 
treatment does not always prevent acute and chronic rejection, and often has serious 
side effects that can lead to other complications, even increased mortality rates.  
Immunosuppressive drugs also have side effects that can compound the problem of 
kidney disease (e.g. cyclosporine [CsA] nephrotoxicity).[18]  It is now widely accepted 
that patients would benefit from reduction of immunosuppression provided that graft 
rejection is prevented; but careful monitoring is essential.   
 
Tolerance Induction 
While pharmaceutical companies attempt to improve immunosuppressant drug 
treatments, other possible pathways to improved long-term transplantation are being 
explored.  One of the major goals in transplantation is the induction of tolerance (i.e. 
indefinite allograft survival without the need for continued immunosuppression by 
medications).  It is possible that induction of graft tolerance, by other mechanisms which 
are “more natural” to the host, may decrease the need for immunosuppressant drugs.   
Tolerance is specific in nature, inhibiting lymphocytes responsible for the rejection of the 
organ, but allowing the immune system as a whole to function normally.  Central 
tolerance results from thymic deletion of T cells with high avidity for thymically 
expressed antigens.  Regulatory T cells (Tregs) have been identified to play a critical 
role in the control of transplant tolerance. [19]  Tregs suppress the proliferation and IL-2 
production of cells in a dose-dependent fashion.  Tregs constitutively express the high 
affinity IL-2 receptor, and therefore, have the ability to outcompete other cells for 
secreted IL-2.[20]  Without stimulation by IL-2, lymphocytes do not undergo growth and 
differentiation.  By defining the stimuli that determine the balance of effector and 
regulatory T cells, it may be possible to reduce the effect of IL-2 on development of 
pathogenic effector cells.[21]   
Studies have also shown that dendritic cells (DCs) have a key role in the immune 
response and are required for full tolerance induction.[22]  The principal function of 
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dendritic cells is to present antigens, but they also play a role in central tolerance.  Only 
dendritic cells are capable of inducing a primary immune response in resting naïve T 
lymphocytes.  Dendritic cells express various receptors (e.g. ILT3) involved in immune 
regulation of antigen presenting cells (APCs) and Tregs.  Dendritic cells are abundantly 
found in the thymus, where they contribute to the negative selection of T cells; T cells 
that respond to DCs carrying self-peptides are destroyed.  Dendritic cells could 
contribute to peripheral tolerance by inducing apoptosis of T cells with high avidity for 
certain MHC/peptides, by inducing anergy in T cells with low avidity for certain 
MHC/peptides (antigen-specific tolerance), and/or by producing IL-10 (which stimulates 
Tregs).  It is not surprising that DC-based therapies for inducing tolerance are of 
foremost interest.  Tolerance induction, using DCs primed with graft MHC/peptides, 
could prevent organ rejection and thus make possible the increase of available organs 
by decreasing the number of re-transplants.  By inducing cell-specific or antigen-specific 
tolerance, it may be possible to reduce or eliminate the use of harsh 
immunosuppressant drugs (operational tolerance). 
 
Hypotheses and Theoretical Framework 
Until a broader understanding of tolerance mechanisms and improved 
immunosuppressant drug protocols are available, other solutions to the lack of available 
kidneys must be explored.  As the ethical and statistical debates continue regarding 
utility-based kidney allocation, we approached the issue from the opposite angle.  
Rather than focusing on allocation and direct expansion of the donor pool, we 
concentrated on development of a post-transplant monitoring tool and retention of 
transplanted organs, as an indirect mechanism for increasing the number of available 
kidneys.  Maximizing the life of kidney allografts post-transplantation is one way of 
reducing the strain on limited resources.  If a transplanted patient looses their first 
kidney allograft, they are more often than not relisted for a subsequent transplant.  The 
first graft is wasted, and now that patient stands to be transplanted with a second kidney 
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that could have been allocated to someone else.  Through careful post-transplant 
monitoring perhaps that patient would have retained their allograft and there would not 
have been need for a second graft transplant, allowing the opportunity for others to 
receive a kidney.    
 An immunological risk scoring system would allow surgeons and nephrologists to 
predict graft loss earlier, possibly avoiding further renal damage and subsequent graft 
loss, while potentially allowing for reduction of immunosuppression.  Unfortunately, 
when acute rejection (AR) is suspected, based on lab test results (i.e. elevated serum 
creatinine), damage to the kidney allograft is nearly established.  A definite diagnosis 
can only currently be made by renal biopsy, an invasive procedure that is often 
associated with severe complications.[23]  Even though improved immunosuppressant 
protocols have reduced the rate of AR, AR is still a major cause of graft dysfunction and 
later loss.[24]  We lack appropriate non-invasive methods to be able to predict, 
diagnose, and reduce risk of rejection during the first year of kidney 
transplantation.[25,26]  Utilizing immunologic factors that are available to clinicians 
across the United States, we developed a model to predict graft function at 1 year and 
at 3 years post-transplant. These models include the traditional factors:  the degree of 
matching of human leukocyte antigen (HLA) typing for each donor and recipient pair, 
pre-transplant anti-HLA antibody levels, and demographics including ethnicity, gender, 
and age.  We also develop an expanded model that includes the factors listed above, as 
well as additional factors, which we deem advantageous to more precise prediction of 
kidney graft outcome at 1 year and at 3 years.  These supplementary factors include: 
degree of matching of major histocompatibility complex class I chain-related gene A 
(MICA) between donor and recipient, degree of matching for killer cell immunoglobulin-
like receptor (KIR) typing between donor and recipient, identification of MICA 
antibodies, and sCD30 level.  Testing kits for these additional factors are available 
through multiple vendors, and are simple to use.  The hypothesis is that incorporating 
these additional tests into routine testing for donors and recipients will allow clinicians to 
use the expanded scoring models as a post-transplant tool.  This tool will predict risk of 
kidney graft outcome and allow for monitoring of changes in immunosuppressant 
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therapies, more accurately, less invasively, and more timely than the current methods.  
This model is one of very few available non-invasive post-transplant monitoring tools, 
and to our knowledge, this is the first time a single model has been proposed utilizing 
MICA, KIR, sCD30, and traditional HLA testing on the same individual study population.  
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CHAPTER II:  REVIEW OF LITERATURE 
 
In order to develop a model for predicting risk of graft function, one must understand the 
principal mechanisms of kidney rejection.  While many aspects of the human immune 
system continue to be a mystery, there are immunologic factors which have been 
proven through years of research to be key players in the process of kidney transplant 
rejection.  For each recipient and potential donor, these conventional factors are 
assessed during evaluations which include laboratory testing and collection of patient 
history.  This chapter seeks to outline the established central factors affecting renal 
transplant immunology, as well as, elucidate several supplementary tests, which may 
have a correlation with kidney graft outcomes.   
 
Conventional Elements of Renal Transplantation 
 
Major Histocompatibility Complex (MHC) —Human Leukocyte 
Antigens (HLA) 
Transplanted organs express two types of alloantigens: major and minor.  Major 
alloantigens include MHC class I and class II molecules.[27,28]  Minor histocompatibility 
antigens (mH-Ags) are peptides, derived from polymorphic proteins, and indirectly 
presented to host T cells by MHC molecules.[29]  These peptide/MHC complexes are 
recognized by host T-cells as “foreign” antigens, and activate a T-cell response, which 
may destroy the graft.[30]  The activation of T cells by mH-Ags has been implicated in 
bone marrow (BM) and hematopoietic stem cell (HSC) transplants as a cause of graft-
versus-host (GvH) disease.[31,32]  Activation of T cells by mH-Ags does not result in a 
significant immunologic attack against kidney allografts, and therefore, identification of 
mH-Ags is not performed during routine testing of transplant patients and donors.[31]     
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The major MHC antigens, however, were first discovered because of the fundamental 
role they play in transplant rejection.  MHC molecules, referred to as human leukocyte 
antigens (HLA) in humans, are routinely identified by DNA testing in both transplant 
recipients and donors.  Whenever possible, recipients with a certain HLA type are 
matched with a potential donor of the same HLA type, because despite advances in 
immunosuppressant therapy, HLA matching continues to have a considerable effect on 
graft survival.[33]  The number of disparities in HLA types between recipients and 
donors (referred to as mismatches) has been shown to be a risk factor for first-year 
acute rejection, and that these first-year acute rejection episodes are associated with 
decreased graft survival at 5 years after transplantation (n = 208).[34] 
The polymorphic genes that encode the MHC are found on chromosome 6 in humans 
and are split into two classes: MHC class I (HLA-A, -B, -C) and MHC class II (HLA-DR, -
DQ, -DP).  The primary function of these antigens is to serve as recognition molecules 
in the initiation of an immune response.  HLA antigens on specialized immune cells 
present peptides to effector cells, which set into motion the cellular and humoral arms of 
the immune response.  The branch of the immune response activated depends upon 
the class of the presenting MHC molecule.   
 MHC class I molecules are found on all nucleated cells and act as indicators of the 
cell’s health.  MHC class I molecules bind peptides generated through an endogenous 
pathway, drawing their peptides from within the host cell.  If a cell is genetically deficient 
(mutant) or infected (e.g. virus), it does not generate its normal assortment of peptides 
(including self-peptides).[27,28]  MHC class I interaction with effector cells initiates the 
cellular immune response.  When there is a reduced cell surface amount of self MHC 
class I molecules, or a foreign MHC/peptide complex is displayed on the cell surface, 
the affected cell becomes “flagged” as defective (the “missing-self” hypothesis).[35]  
CD8+ cytotoxic T cells (CTLs) and natural killer (NK) cells are able recognize different 
levels of MHC class I expression and foreign MHC/peptide complexes via their 
receptors.[36,37]  If CTLs and NK cells do not recognize the appropriate level of self 
MHC class I on a cell’s surface, they initiate destruction of that cell via apoptosis. 
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MHC class II molecules are found on antigen presenting cells (APCs) and bind peptides 
generated through an exogenous pathway.  APCs continuously sample the extracellular 
environment by an endocytic process.  External macromolecules are taken into an 
endosomal or lysosomal compartment where they are degraded.  The resulting peptide 
fragments are co-assembled with MHC class II molecules and then delivered to the cell 
surface for expression and interaction with CD4+ T helper cells, which activates the 
humoral immune response.[36,37]  The humoral response is a result of cytokine 
secretion by type 1 T helper cells (IL-2, IFN-γ, and TNF-α) and type 2 T helper cells (IL-
4, IL-5, IL-15, and TGF-β).  These cytokines drive proliferation and differentiation of T 
and B lymphocytes, including B cell isotype switching which results in production of 
antibodies that mediate opsonization, complement fixation, and Antibody-mediated cell-
mediated cytotoxicity (ADCC).  
MHC is the driving force behind the ability of the immune system to detect genetic 
polymorphisms between members of the same species in a process referred to as 
allorecognition.[38]  In renal transplantation, there are two main mechanisms of 
allorecognition, direct and indirect.  In direct allorecognition, host T cells interact with 
donor peptides presented by donor APCs.  This occurs when donor “passenger 
leukocytes” migrate out of the graft to the host’s lymphoid tissues.  The direct pathway 
leads to the early sensitization of host to donor antigens, which can lead to acute 
rejection.[39]  This response diminishes over time regardless of whether or not chronic 
rejection occurs.[40]  Indirect allorecognition occurs when host APCs migrate into the 
graft, take in and process donor antigens, and present these processed donor peptides 
to host T cells.[41,42]  In contrast to direct allorecognition, the response generated by 
the indirect pathway can persist and has been correlated with chronic rejection.[40] 
With regard to transplantation, HLA antigens play a major role in the rejection of foreign 
tissue.  Before the recent era of new immunosuppressive drugs, patients who were well 
matched for HLA loci had better graft survival than recipients who were not well 
matched.[43,44]  The HLA system is the most polymorphic system in the human body 
and not all antigens are represented with the same frequency in all ethnic groups.  
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Some antigens only occur in certain ethnic groups and have very low frequency within a 
given population.  Patients with rare or uncommon HLA phenotypes are at a 
disadvantage in regards to finding a good match.[45,46]   New and more powerful 
immunosuppressive treatments have increased the survival for poorly matched 
recipients, and driven organ allocation in the United States away from 'matching' and 
more towards equality in allocation and overall survival benefit.[46]  However, 
mismatches still present a risk for development of antibodies and subsequent graft 
rejection.  How well matched an organ is for its recipient should be considered when 
altering immunosuppressant regimens.  
 
Panel Reactive Antibodies (PRA) 
The percent PRA value is a measure of a patient’s level of sensitization to donor 
antigens.  It is the percentage of cells from a panel of blood donors against which a 
potential recipient’s serum reacts.  The PRA reflects the percentage of the general 
population that a potential recipient makes antibodies (is sensitized) against.  The 
higher the PRA, the more sensitized a patient is to the general donor pool, and thus the 
more difficult it is to find a suitable donor.   Antibodies against HLA antigens are not 
naturally occurring and arise following “sensitizing events,” such as pregnancy, 
transfusion, or previous transplantation.  Finding an acceptable graft for a patient who is 
highly sensitized depends on correctly identifying all HLA antibodies present in patient’s 
sera.  A potential allograft recipient with a high percentage (>80%) of preexisting 
antibody against HLA antigens (PRA) is often at a higher risk of a positive crossmatch, 
which implies a high risk of rejection.[47]  Since crossmatching was established as a 
pre-transplant screening method, hyperacute rejections have been almost 
eliminated.[48,49]   
There is a lack of standardization in regards to PRA levels between laboratories, due to 
the diverse methodologies currently performed by the individual HLA laboratories. 
Despite the increased sensitivity of the current methods for detecting PRA, there are 
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some HLA antigens and alleles not represented in the panels used by labs.  Many labs 
run a battery of different panels in an attempt to avoid overlooking any donor specific 
antibodies (DSA) present.  As the sensitivity of testing increases, so does the debate 
regarding the clinical significance of the antibodies detected.  Antibodies detected using 
the most sensitive techniques (i.e. solid-phase single-antigen testing), may not be 
detected by other methods (i.e. antibody screens or multi-antigen phenotypes) and may 
not always result in a positive crossmatch. Which leads to the question:  Are these 
antibodies clinically significant?  In other words, are these antibodies “strong” 
(immunogenic) enough to initiate a rejection response?  How each lab interprets their 
testing panels, in response to this question, determines what PRA is reported to the 
transplant center.   Thus, achieving standardization between labs continues to be a goal 
among several histocompatibility societies.  
Antibodies against donor HLA antigens are considered contraindicative to 
transplantation, and the antigens they react against are called “unacceptable antigens.”  
These unacceptable antigens are listed for each recipient on the national waitlist.  The 
United Network for Organ Sharing (UNOS), the organization that manages the United 
State’s organ transplant system, implemented new policies in 2007 which deemed that 
PRA percentages be calculated based on antigens that are assigned as unacceptable 
in the UNOS database system and the frequencies of those antigens in the donor 
population.[50,51]  The calculated PRA computes the PRA percentage using both anti-
HLA class I and class II antibody specificities, assigned to each patient as 
unacceptable, and knowledge of the frequency of the assigned unacceptable HLA 
antigens in a representative population.  This has alleviated some of the problems in 
standardization of PRA reporting.   
While acute rejection (AR) of kidney allografts primarily occurs through a T cell 
mediated mechanism, several studies have shown that antibodies are involved in some 
acute and possibly chronic rejections.[52,53]  Antibody-mediated acute rejection (AMR), 
also called acute humoral rejection (AHR), occurs in 20-30% of AR episodes.[54,55]  
Diagnosis of AMR relies on detection of circulating donor-specific antibodies and 
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histological evidence (i.e. C4d staining of graft biopsies).[56,57]  The presence of DSA 
(antibodies that react with a donor’s specific HLA antigens) before and after kidney 
transplantation is associated with rejection episodes and graft loss (n = 29).[58]  
Patients with high percent PRA are at greater risk of rejection.[59,60,61,62]  During the 
first year post-transplant, presence of either class I or II DSA has been associated with 
poor graft survival, even when C4d staining of biopsy was not indicative of AMR.[52,53]  
This same study found that after the first year, those with class II DSA and C4d positive 
had worse graft outcomes (n = 297).[52]  These studies reaffirm the need to better 
define which diagnostic criteria are useful for AMR and serve as a reminder that the 
time post-transplant should be taken into consideration when interpreting C4d staining.   
In summary, antibodies against a donor’s HLA antigens present before transplantation 
are associated with reduced graft survival and are contraindicative to 
transplantation.[63]  Those antibodies found post-transplant, but before graft failure is 
detected (e.g. increase serum creatinine levels), are worth monitoring as they are likely 
the most significant cause of later graft failure.  Antibodies developed post-transplant 
may take years to destroy the graft and the graft may function well for years despite the 
presence of antibodies (n = 948).[64]  The time between transplantation and antibody 
development is under investigation to determine if it affects graft survival.  
 
Affects of Age, Sex, and Ethnicity on Graft Outcome 
 
Age 
In addition to the immunological factors routinely tested for by histocompatibility labs, 
factors such as age, sex, and ethnicity can also be risk factors for graft failure (n = 
125).[65]  In elderly kidney transplant recipients, the most frequent cause of graft loss is 
death with a functioning graft due to infectious disease or cardiovascular causes (n = 
38,836).[66]  Recipients over the age of 60 have an increase risk of dying due to 
infection after transplant and are considered poor immune responders.  Older recipients 
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who experience an acute rejection episode often have shorter graft and patient 
survival.[67,68]  Compared to those under age 50, an increased risk for graft loss has 
been associated with donors and recipients over age 50, and the combination of a 
donor and recipient both over age 50 may act synergistically to affect graft survival 
[69,70,71].  This has led to a selection bias for allocating kidneys from old donors to 
older recipients in an attempt to optimize the usage of kidneys.  In his paper, The 
Impact of Age on Rejection in Kidney Transplantation, de Fijter outlines the premises 
behind this:[67] 
“1. Elderly recipients are less likely to mount an acute rejection response. 
2. The functional capacity of a kidney graft allocated to an elderly recipient may 
be limited as elderly recipients have diminished metabolic demands. 
3. Older recipients have a shorter life expectation and can therefore receive 
grafts with a limited long-term prognosis. 
4. Kidneys from old donors are more vulnerable to delayed graft function than 
kidneys from younger donors. 
5. Kidneys from old donors are more likely to reject. 
6. Kidneys from old donors are less likely to mount an adequate repair response 
following injury.”[67] 
 
However, several registry data studies and single-center studies do not support the 
hypothesis that older recipient age is a risk factor for chronic allograft nephropathy 
(CAN), but do not refute that acute rejection episodes are associated with an increased 
risk of CAN.[72,73]  Alloantigen-independent factors, which may be recipient age-
dependent, such as hyperlipidemia and hypertension have been associated with 
increased risk of CAN, and should be taken into consideration in management of older 
transplant recipients .[74,75] 
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Gender  
One of the most common sensitizing events leading to development of HLA Abs in 
women is pregnancy.  Women who have been sensitized to paternal HLA antigens 
through pregnancy are at risk for graft rejection if those same paternal HLA antigens are 
shared by the donor organ.  In cases, where antibodies have been formed, primed 
cytotoxic T lymphocytes (CTLs) directed against the same paternal HLA antigens can 
persist for more than 10 years after pregnancy.[76,77] 
Until recent years, women who had received a transplanted graft were strongly 
discouraged from becoming pregnant.  It was feared that gestation would pose a threat 
to the graft, mother, and child.  However, female transplant recipients who are carefully 
monitored by transplant nephrologists and high-risk obstetricians can have successful 
pregnancies if the mother maintains a stable creatinine level, insignificant proteinuria, 
and normal blood pressure.  Pregnancy does put both mother and child at a higher risk, 
but when these factors are maintained within normal limits, pregnancy is not necessarily 
detrimental to a previous graft transplant.[78,79]   
Donor gender has been shown to have a correlation with renal allograft survival (n = 
124,911).[80]  Several studies have shown that kidneys from female donors have a 
higher frequency of rejection than kidneys from male donors.[81,82]  Recent attention 
has been focused on examination of this gender disparity through the evaluation of 
several different hypotheses.  One hypothesis states that the size of the female donor 
kidney, relative to the male recipient, may induce nephron overload resulting in 
hyperfiltration-mediated injury and that this is responsible for reduced graft survival.[80]  
Simply put, that some female kidneys are simply too small (and thus have fewer 
nephrons) to meet the needs of a larger male body.  A second hypothesis is that female 
donor grafts are more susceptible to cyclosporine nephrotoxicity or differences in the 
therapeutic response to cyclosporine.[81]   This second hypothesis takes into account 
that there are not only physical size differences in kidneys, but perhaps female body 
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chemistry (e.g. hormones) reacts differently with traditional immunosuppressants 
making them more toxic to the graft or reducing their therapeutic effectiveness.  To the 
contrary however, one study found that female to female transplants after the first year 
have similar graft survival to that of male donor grafts (to any recipient), and had 
significantly higher survival rates than female to male transplants (n = 170).[82]  The 
higher frequency of rejection of female donor kidneys may be due to a combination of 
immunologic and non-immunologic factors which are affected by the gender of the 
recipient. 
Despite the poor functional prognosis of female grafts and the increased possibility of 
sensitizing events (pregnancies), kidney transplants fare better in female than in male 
recipients overall.[83]  Male recipients have a greater risk for kidney graft loss than 
females.[83]  Zeier et al also found that the gender effect was more pronounced for 
younger (16 to 45yr) compared with older (>45 yr) donors (n = 124,911).[80]  Perhaps 
the influence of non-HLA factors, such as hormonal status, should be considered when 
evaluating donors and recipients.  Studies have shown that the immune system 
undergoes intense stimulation in a high-estrogen environment.[84,85]  Females have a 
higher risk of acute rejection, yet have a decreased risk of graft loss due to chronic 
allograft failure (n = 73,477).[86]  These studies indicate that there are important, 
gender-related differences in the immune response that require further investigation. 
 
Ethnicity 
In the genetics era, there is debate among scholars about the significance of race and 
ethnicity in terms of describing human genetic variation.   While geographic location 
may be the best single explanation for human genetic variation,[87]  it does not explain 
those differences between two groups living in the same area.  Race has been used in 
medicine and other fields as a way to categorize both genetics and “lived 
experience.”[88]  Goodman’s theory implies that what appears to be resulting genetic 
differences may actually be due to social interactions (“lived experience”); emphasizing 
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that human biology and health are linked to social, cultural, political, and economic 
processes.[88] While the variation in human biology is too complex to be reduced to race 
alone, information gathered based on race could be reflective of overall health in certain 
populations.  There is substantial evidence that racial and ethnic health disparities are 
strongly associated with social factors, such as lack of access to resources, and also 
racial discrimination. [89]  While race may appear to many as simply a social 
construction, inequalities still persist amongst ethnic groups.  It would be ill-advised for 
healthcare providers to abandon the concept of race altogether.  In transplantation, each 
of these processes is evaluated for the recipient and donor in an attempt to clarify their 
overall state of health and their available health resources, and the designation of race 
or ethnicity is used to indirectly to describe the human variation of that population.   
A regional retrospective study of 20,240 transplants in the southeastern United States, 
found that even though patient survival rates at 1 year do not appear to be significantly 
different among different ethnic groups, ethnicity does play a role in allograft survival.  In 
that study, African American recipients had poorer graft survival than their Caucasian 
counterparts.[90]  Nationally, the 1 year kidney graft survival rates in the United States 
is greatest for Asians, followed in decreasing order by Hispanics/Latinos, Caucasians, 
and African Americans.[1]  Donor kidneys from African Americans have lower graft 
survival when transplanted into Caucasian or African American recipients, and are 
associated with lower patient survival (at 5 years) (n = 72,495) and the highest risk of 
graft loss (after the first year) (n = 77,689) in African American recipients.[91,92]  Graft 
and patient survival for Asian and Latino/Hispanic recipients, while only slightly better 
than graft survival for Caucasian recipients, is independent of donor ethnicity.[91,92]  
However, the limited number of Hispanic and Asian donors and recipients in the U.S. 
population bring these statistics under scrutiny.  To our knowledge, no recent study 
addressing race/ethnicity and kidney allograft outcome has been reported solely specific 
for the state of Tennessee. 
National studies indicate that compared to their Caucasian counterparts, young African 
American recipients (aged 18-49) have a higher risk of acute rejection (which affects 
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long-term graft survival) and graft loss (n = 112,120).[93]  African American recipients 
appear to be more prone to graft loss because of chronic allograft nephropathy (CAN, 
formerly chronic rejection), and major etiologic factors for end-stage renal disease (type 
2 diabetes mellitus and hypertension) are more prevalent in African Americans than in 
the general population (n= 3706).[94]  It is possible that these etiologic factors, which 
were responsible for the original kidney damage, are contributing to the destruction of 
the kidney allograft leading to CAN. 
 Recent studies have shown that ethnicity and gender cannot be treated as totally 
independent risk factors for allograft outcome.  When stratified by ethnicity and gender, 
black females had significantly reduced graft survival (n = 805).[95]  However, when 
African American females were excluded from multivariate analyses, allograft survival 
between African American males and all Caucasians were similar, implying that gender 
may play the critical role in outcome rather than ethnicity.[95]  These studies reinforce 
the need to expand our limited understanding of the human immune response, and 
while research may focus on minute parts of human physiology, their findings contribute 
to the broader comprehension of a person’s overall biological-social health state. 
 
Novel Supplementary Elements of Renal 
Transplantation 
Major Histocompatibility Complex Class I Chain-Related Gene A 
(MICA) 
The major histocompatibility complex (MHC) class I chain related gene A (MICA) is 
possibly the most polymorphic non-HLA antigenic system capable of inducing antibody 
responses involved in hyperacute, acute, and chronic graft loss.  MICA encodes 
proteins that have a similar sequence to MHC class I molecules, are structurally similar 
to MHC class I, and function in natural killer (NK) cell recognition like other MHC class I 
20 
 
molecules.[96,97]  MICA is highly polymorphic and located close to the classical HLA-B 
locus on chromosome 6.[98,99]  MIC molecules show high homology with HLA 
molecules, but they do not bind β2 microglobulin nor do they bind conventional class I 
peptides.[100,101]  MIC acts as a ligand for natural killer (NK) cells, γδ T cells, and αβ 
CD8+ T cells expressing the activating receptor NKG2D.[98,102]  MICA gene 
expression can be induced by cellular stress such as heat, viral infection, inflammation, 
and DNA damage.[101]  In epithelial cells, expression of MICA proteins on the cell 
surface serve as markers for immune surveillance and can activate NK cells and T cells, 
via their NKG2D receptors, to destroy the affected epithelial cell.[101]  Ischemia-
reperfusion injury (IRI)  initiates inflammatory changes in vascular endothelial and 
tubular epithelial cells, leading to upregulation of the expression of adhesion molecules 
and MICA.[103]  MICA proteins have been found in various cells/tissues, including all 
major organs except the brain;[98] however, they are mainly expressed in 
gastrointestinal epithelium, endothelial cells, and fibroblast.[104]  MICA proteins have 
been observed in tissue samples from kidney allografts in both acute and chronic 
rejection.[105]  While there is no pharmacological way of preventing kidney injury 
caused by IRI, reducing the role of MICA through MICA matching of recipients and 
donors (and subsequent prevention of the development of MICA DSA), may improve 
kidney transplant outcomes.  
Sensitizing events for MICA antibodies are the same as for HLA antibodies.[106]  
Mismatched MICA donor antigens encountered after kidney transplantation may result 
in antibodies against MICA alleles.  There is evidence that MICA antibodies, in addition 
to HLA antibodies, are associated with graft failure [107,108,109,110] and these 
antibodies have been suggested as a cause of acute and chronic rejection when HLA 
antibodies are not present.[102,111,112]  Most studies to date have only performed 
MICA genotyping or checked for presence of MICA Abs, not both.  If antibody testing is 
not performed, establishing if MICA genotype mismatching between donor and recipient 
elicits a clinically significant antibody response becomes problematic.  Likewise, if 
genotyping is not performed on the donor-recipient pair, one is unable to definitively 
classify MICA Abs as DSA allo-antibodies or auto-antibodies against self MICA Ags.  As 
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with antibodies to self-HLA antigens, it is unlikely that antibodies against self-MICA 
molecules would cause kidney loss, but donor-specific MICA antibodies from pre-
sensitizing events may cause allograft rejection.  Another limitation to current MICA 
studies is the lack of pre-transplant testing for MICA antibodies and post-transplant 
following of MICA antibody development.  Without being able to determine if antibodies 
are against self-antigens or donor antigens (MICA genotyping of both recipient and 
donor) and when these antibodies developed (pre- and post-transplant MICA antibody 
testing), one cannot make an accurate interpretation of the role that MICA antibodies 
play in rejection.  
 
Killer-cell immunoglobulin-like receptor (KIR) 
Killer-cell immunoglobulin-like receptors (KIRs) were first identified as receptors found 
on natural killer (NK) cells that could induce cytolysis.[113,114]  KIR can be expressed 
by NK cells and CD8+ T cells.[115]  NK cell function depends on the interaction of KIR 
ligands with inhibitory and/or activating KIRs.  The interaction of KIRs with their ligands 
is determined by the KIR cytoplasmic tail.[116,117]  Long intracellular tails (designated 
“L”) give inhibitory signals due to the immunoreceptor tyrosine-based inhibition motifs 
(ITIMs) in the tail. Where short tails (designated “S”,) transmit activating signals through 
immunoreceptor tyrosine-based activation motifs (ITAMs).[116,118] 
  KIR ligands are HLA class I molecules.    Inhibitory KIRs have a high affinity for 
different subsets of HLA class I molecules.[119,120]  HLA-C and HLA-Bw4 are ligands 
for inhibitory KIR2DL and KIR3DL respectively.[121,122,123]  All NK cells can express 
several KIRs, but at least one of these is inhibitory under normal conditions.  Down-
regulated expression of MHC class I expression in infected or transformed cells can 
result in destruction by NK cells, termed the “missing-self hypothesis”.[35]  Under 
normal conditions, cells express normal levels of HLA class I molecules.  When these 
cells are damage, the surface expression of HLA is decreased.  NK cells interact with 
these transformed cells and do not receive the appropriate “self HLA” inhibitory signal.  
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NK cells then induce apoptosis of these transformed cells.  The same self/non-self 
recognition by NK cells mediates NK alloreactivity in renal allograft transplantation, and 
the missing expression of self HLA molecules on donor cells can be potential targets of 
NK cell killing.  This “missing ligand” hypothesis states that for each KIR expressed in 
the recipient, the inhibitory ligand (HLA-associated epitope) needs to be present on (or 
be “matched” to) the donor cells to avoid NK cell alloreactivity.[124,125] 
It has been suggested that some specific recipient receptor--donor ligand combinations 
might be associated with acute rejection episodes in renal transplantation with KIR/HLA 
incompatibility and that an imbalance of activating and inhibitory receptors may 
contribute to poor allograft outcome.[126]  A higher number of inhibitory receptors in the 
recipient's genotype and matching for the receptors KIR2DL2 and KIR2DS2, has been 
observed in patients with stable kidney graft function (n= 224).[126]   Another study of 
12 HLA-matched sibling recipient-donor pairs found that when both genotypes lack 
KIR2DL2 and KIR2DS2, there was a higher risk for poor graft function.[127]  These 
studies are based on the theory that recipient NK cell cytotoxicity against donor cells is 
the result of the recipient’s lack of the correct inhibitory receptors, or an overabundance 
of activating KIRs.[128]  Such imbalances could result in excessive activation of NK cell 
alloreactivity against the donor graft cells.  One study evaluated whether acute rejection 
in kidney transplants (occurring after immunosuppression was reduced) was associated 
with the predicted NK cell alloreactivity based on KIR gene and ligand analysis.  In that 
study, HLA and KIR genotypings of 69 recipient-donor pairs were used to analyze the 
presence of KIR genes, and to predict NK cell alloreactivity based on the "missing self" 
and "missing ligand" hypothesis.[125]    While the findings were solid, the study 
population was limited.  In another study of 2,757 transplants, kidney recipient-donor 
pairs were separated according to their HLA-Cw alleles and HLA-Bw4 specificity (which 
are ligands for KIR) and NK cell alloreactivity was predicted based on the missing ligand 
hypothesis.[129]  However, this study did not perform typing of KIR genes.  Neither 
study could identify a significant relationship between KIR ligand matching and renal 
graft survival.   
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Very little is known about the expression of inhibitory and activating KIRs on T-cell 
subsets, and to our knowledge, there is currently no data on T-cell expression of KIRs in 
the post-transplant period.  One study by Henel et al found evidence that inhibitory KIRs 
can change the T-cell effector profile by altering transcription of T cell receptor genes, 
without affecting granule release and cytotoxicity.[130]  While these studies 
demonstrate a potential role of certain KIR/HLA ligand interactions in renal 
transplantation, the biological and functional aspects of KIR receptors still need to be 
explored in a clinical setting.  Analysis of KIR expression on graft infiltrating NK cells 
and T cells, as well as their interactions with ligand-expressing cells, may provide 
valuable insight. 
 
Soluble CD30 (sCD30) 
 
The CD30 molecule was originally discovered as an antigen on the surface of Hodgkin 
and Reed Sternberg cells.[131]  CD30 is a member of the tumor necrosis factor/ nerve 
growth factor receptor superfamily and is expressed on T cells that produce Th2-type 
cytokines.[132,133,134,135]  During immune responses that activate these T cells, a 
soluble form of CD30 (sCD30) is released into the blood.[135]  An association between 
CD30 expression and Th1 cytokine production has also been suggested.[136]  It has 
also been hypothesized that CD30 functions as a co-stimulatory molecule, acting as a 
marker for the balance between Th1(cellular) and Th2 (antibody-mediated) 
responses.[137]  While the exact role of CD30 is unclear, elevated pre- and post-
transplant sCD30 levels have been associated with an increase risk of rejection and 
graft loss.[138,139,140] 
Biopsy results were unavailable in many of the early studies regarding sCD30.  
Therefore, they were unable to determine whether patients with a high sCD30 were 
more prone to antibody-mediated or cell-mediated rejection.  Studies comparing pre- 
and post-transplant serum levels of sCD30 have been performed, but their focus was 
limited to acute rejection episodes in the first post-transplant year.[140,141,142,143]  In 
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the American Journal of Transplantation in 2005, Rajakariar et al, using 108 renal 
transplant recipients, correlated the levels of sCD30 at time of transplantation with the 
grade of rejection utilizing standard C4d biopsy immunostaining, but did not perform any 
post-transplant sCD30 testing and were limited to a maximum 5 year post-transplant 
follow-up period for determining graft outcome.[144]  Poorer graft outcomes have been 
observed in patients with both PRA and high sCD30 serum levels before transplant, and 
high levels of pre-transplant sCD30 have been associated with lower five-year graft 
survival in kidney transplant patients.[145,146]  High pre-transplant levels (>100 U/ml) 
of sCD30 have been linked to acute allograft rejection;[140,146,147] however,  other 
studies indicate that pre- and post-transplant sCD30 levels are not predictors for acute 
kidney rejection, nor are they useful for monitoring during reduction of 
immunosuppressive drugs.[148,149] 
Very few of these studies took into consideration other factors (those not specific to 
transplantation) which could also lead to increased sCD30 in transplant recipients.  
Interpretation as to the true relationship of sCD30 and acute rejection must be done 
carefully, with knowledge of the patient’s entire immune status.  Increased levels of 
sCD30 have been noted in various conditions such as virus infections, autoimmune 
disorders, pregnancies, and some tumors.[136,150,151,152]  Since elevated sCD30 is 
not only associated with graft rejection, but also with states of increased immune 
reactivity, general classification of sCD30 levels (low to high) and interpretation of their 
relevance, should be done with caution.  An increased level of sCD30 in a transplant 
recipient with rheumatoid arthritis may not be indicative of increased risk of kidney 
allograft rejection, but rather a reflection of increased Th2 activity due to the arthritis.  
Monitoring patient’s sCD30 levels before and after transplantation, and then evaluating 
the change in concentrations, rather than categorizing levels as low to high, may 
provide useful insight into the correlation of sCD30 to graft function and survival. 
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Summary 
Prediction of graft outcome proves to be a multi-facetted problem.  There are numerous 
immunological and non-immunological factors that can contribute to graft loss, and until 
we can elucidate tolerance mechanisms and ameliorate immunosuppressant drug 
protocols, we should utilize our current knowledge to advance graft function.  We 
propose to assess each of the factors outlined in this chapter for both individual, as well 
as collective risk effect on graft outcome on the same individual study population.  
These factors include the traditional factors (HLA matching for each donor and recipient 
pair, pre-transplant PRA levels, and standard population demographics) and 
supplementary factors (MICA matching between donor and recipient, KIRmatching 
between donor and recipient, identification of MICA antibodies, and sCD30 level).  
Testing kits for each of these factors are available to laboratories across the United 
States, and therefore, can easily be obtained for testing at other centers.  After 
evaluation of each factor, we anticipate that we will be able to provide clinicians with a 
model that will aid them in the prediction of kidney graft outcome in the years after 
transplant and thus allow them to alter individual patient’s immunosuppressive protocols 
accordingly.  This novel tool will predict risk of kidney graft outcome and allow for 
monitoring of changes in immunosuppressant therapies, more accurately, less 
invasively, and more timely than the current methods.   
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CHAPTER III:  SUBJECTS AND METHODS 
 
Definitions 
 
Traditional Risk Score / Model 
Currently, kidney transplant surgeons and nephrologists across the United States have 
access to a “standard” group of variables used not only for optimal allocation of organs, 
but also to predict graft outcome.  These variables include the recipient’s PRA, recipient 
and donor ethnicity, gender, age, HLA typing of A, B, DR, and DQ loci.  While each of 
these variables has been shown to have an effect on graft outcome, they are insufficient 
for accurate prediction of graft function.  We used these factors to develop a model, 
which may be used by clinicians to help gauge the risk of graft outcome after kidney 
transplantation for a specific donor-recipient pair.  This model was termed “Traditional 
Risk Score.” 
 
Expanded Risk Score / Model 
Addition of other variables may increase the predictive ability of the scoring system.  
After consideration of current literature and availability of reagent test kits, we selected 
additional variables for evaluation:  MICA typing, MICA Ab testing, KIR typing, and 
sCD30 level monitoring.  Each variable was evaluated for inclusion in a second scoring 
system, termed “Expanded Risk Score.”  This expanded risk model included all the 
variables in the traditional risk model and additional test variables: MICA matching 
between recipient and donor, KIR matching between recipient and donor, pre-transplant 
level of sCD30 in the recipient, and detection of pre-transplant MICA antibodies.   
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Study Subjects 
The United Network for Organ Sharing (UNOS) and the University of Tennessee 
Medical Center in Knoxville collect extensive data on transplant patients both pre- and 
post-transplant.  At the time of transplant, these reports include recipient-donor pair 
demographic characteristics such as age, gender, ethnicity, PRA, HLA matching.  
 
Statewide Population 
The statewide study population consisted of 694 adult (age range 19-78 years) kidney-
only, standard criteria deceased donor transplant recipients in Tennessee (excluding 
those from the University of Tennessee Medical Center, Knoxville, TN [TNUK]) from 
2005 to 2008.  A description of the study population is shown in Table 1(See 
APPENDIX).  Of these 694 recipients (465 men and 229 women), 624 patients (89.9%) 
were reported to have a functioning graft at 1year post-transplant as indicated to UNOS 
on the Transplant Recipient Follow-Up Form (Table 3. See APPENDIX).  Their 
corresponding deceased donors ranged from 1year to 59 years of age (446 men and 
248 women).   Ethnicity of recipients included 389 Caucasian and 305 African 
American.  Ethnicity of donors included 587 Caucasian and 107 African American.  
Other ethnicities made up less than 4% of the study population and were therefore 
excluded from the study.  Of the 455 recipients not lost to follow-up, 373 had a 
functioning graft at 3 years post-transplant (82.0%) (Table 3. See APPENDIX).  
Recipient and donor data were obtained from UNOS using an encrypted study 
identification number to protect confidentiality of the subjects.  Since samples were not 
available, no additional testing was performed on this population for the purposes of this 
study. 
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TNUK Population 
All adult (age range 20-74) kidney-only, standard criteria deceased donor transplant 
recipients at the University of Tennessee Medical Center (Knoxville) [TNUK] from 2005 
to 2008 were evaluated for retrospective analysis (N=113).  The cohort study subjects 
(recipient-donor pairs) were enrolled into this study if they had stored genomic DNA and 
stored pre-transplant sera from day of transplant or within 3 months prior to transplant.  
Stored genomic DNA of the corresponding deceased donor was also required.  A 
description of the TNUK study population is shown in Table 2 (See APPENDIX).  
Previously stored samples were available on 64 of the recipient-donor pairs.  These 
were tested for MICA, KIR, and sCD30.  Of these 64 pairs, 62 had a functioning graft at 
their 1-year post-transplant follow-up (96.9%) (Table 3. See APPENDIX).  A non-
functioning graft was defined as the need for or return to dialysis treatments.  Of the 
remaining 62 patients, 58 had a functioning graft at their 3-year post-transplant follow-
up (93.5%) (Table 3. See APPENDIX).  The recipient age range was from 20 to 74 
years (45 men and 19 women).  The donor age range was from 12 to 66 years (39 men 
and 25 women).  Ethnicity of recipients included 61 Caucasian and 3 African American.  
Ethnicity of donors included 59 Caucasian and 5 African American.  Other ethnic groups 
made up less than 2% of the study population and were therefore excluded from the 
study.  Each donor-recipient pair was given a unique, numerical identifier to ensure 
patient confidentiality.  The study was approved by the Institutional Review Board of the 
University of Tennessee, Knoxville (# 8159B) and by the Institutional Review Board of 
the University of Tennessee, Graduate School of Medicine (# 2988). 
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Additional testing:  MICA, KIR, sCD30 
Commercially available kits were used for all additional testing to ensure that these   
tests could be performed by HLA laboratories throughout the United States, thus 
allowing clinicians to utilize the expanded scoring system. 
DNA samples from recipients and donors, previously collected during routine testing, 
were stored at -20°C until used.  MICA genotyping was performed with LABType SSO 
MICA (One lambda Inc.), according to the manufacturer’s instructions.  KIR genotyping 
was performed using LABType SSO KIR (One lambda Inc.), according to the 
manufacturer’s instructions.  A match for MICA tying was evaluated the same as 
traditional HLA matching:  a direct comparison of genotype.  KIR matching was 
evaluated by comparison of the KIR receptor typing of the recipient to the presence or 
absence of its corresponding HLA ligand in the donor.  Utilizing the classification 
scheme developed by Holm et al, each recipient KIR-donor HLA pair was classified 
according to the expected NK cell response: balanced, excess inhibition, excess 
activation, or undetermined.[153]  
Pre-transplant recipient sera, collected on day of transplant or within 3 month prior to 
transplant, was stored at -20°C until use.  Soluble CD30 levels were obtained from sera 
using Human sCD30 Flow Cytomix Simplex (eBioscience) according to the 
manufacturer’s instructions.  MICA antibody identification was performed using 
LABScreen MICA Single Antigen kits (One Lambda, Inc.) according to the 
manufacturer’s directions. 
 
Statistical Analysis 
Characteristics of the study populations were summarized using descriptive statistics, 
including absolute numbers and percentages for categorical variables, and means and 
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standard deviations for continuous data.  The predictors of interest were assessed by 
univariate analysis, and then in multivariate models adjusting for potential confounders.  
 
Variables 
Outcomes: 
• Categorical outcomes:  Graft functioning or graft not functioning.  A graft was 
considered non-functioning if the patient required dialysis.  This was measured at 
one year post-transplant and at three years post-transplant for both the standard 
and expanded model populations. 
• Continuous outcomes:  Serum creatinine levels (mg/dL) at 12 months post-
transplant were evaluated in the expanded model population as an alternate 
measure of outcome at 1 year post transplant. 
Predictor variables:   
• Age (continuous-scale) 
• Ethnicity/Race (categorical-nominal)—Caucasian/White or African 
American/Black 
• Sex/Gender (categorical-nominal) 
• PRA (categorical-nominal)—PRA between:  0 – 19%, 20 – 39%, 40 – 79%, and 
above 80% (divisions based on what is widely accepted as zero to very low, low, 
moderate, and high levels of PRA) 
• HLA matching (categorical-nominal)—Class I HLA: AB loci match or AB loci 
mismatch; Class II HLA: DRDQ loci match or DRDQ loci mismatch.  While other 
HLA antigens have proven valuable for prediction of graft outcome, they are not 
uniformly or routinely tested for by all HLA laboratories in the United States. 
• KIR matching (categorical-nominal)—balanced, excess activation, excess 
inhibition, or undetermined.  Note: The study population only had balanced or 
excess inhibitory receptor matches. 
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• MICA matching (categorical-nominal)—MICA match or MICA mismatch 
• Soluble CD30 (pg/mL) (continuous-scale) 
• MICA antibodies (categorical-nominal)—present or absent.  Note: Presence of 
DSA and auto-Ab analysis was examined, but not included in the statistical 
development of models due to the small number of cases with DSA or auto-Abs. 
• Serum creatinine (mg/dL) (continuous-scale) at 1 month, 6 months, and 12 
months post-transplant.  These were evaluated as predictors for the 
functioning/non-functioning outcomes. 
 
Univariate Analysis and Descriptive Statistics 
Continuous Variables 
Descriptive statistics were calculated on all continuous variables.  Continuous variables 
were assessed for normality (Shapiro-Wilk test, skew, and kurtosis) and for 
homogeneity of variance (Levene’s test and Moses Extreme Reactions).  Data 
transformations (log transformation and square root transformation) were used to 
correct for non-normality and unequal variances without success.  For the 12 month 
creatinine outcome, all non-parametric continuous variables were tested for correlation 
using Kendall’s tau (2-tailed).   For the functioning/not functioning outcome at 1 year 
and 3 years post-transplant for both the traditional and expanded model populations, 
continuous variables were analyzed using logistic regression.  Statistical significance 
was set at p  0.05. 
Nominal Variables 
Frequencies were calculated for all nominal variables.  Independent samples tests were 
performed for nominal variables and the 12 month creatinine outcome using Kruskal-
Wallis, Mann-Whitney, Kolmogorov-Smirnov Z, and Jonckheere-Terpstra test for 
ordered alternatives.  Cramer’s V, Pearson chi-square test, and the likelihood ratio were 
calculated for all nominal variables and the functioning/not functioning outcome at 1 
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year and 3 years post-transplant for both the traditional and expanded model 
populations.  Statistical significance was set at p  0.05. 
 
Generation of Models and Appropriateness of Design 
Twelve total models were generated to assess outcome at 1year post-transplant and at 
3 years post-transplant for the standard and expanded model populations.  Binary 
logistic regression was used to generate both the traditional scoring system and 
expanded scoring system models using SPSS software (version 19; SPSS Inc.).  
Independent risk factors for graft failure were identified using Backward Stepwise 
(Likelihood Ratio) selection from multivariable logistic regression.  
Each model was assessed for goodness of fit using the model chi-square statistic and 
the -2 log-likelihood (-2LL).  The overall significance of each model was measured by 
Cox and Snell’s Rcs2  and Nagelkerke’s RN2 .  Statistical significance was set at p ≤ 0.05. 
The predictive ability of each model was evaluated for sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV), false positive rate (FP), and 
false negative rate (FN).  It is acceptable for these models to have a higher type I error 
and more false positives than false negatives.  This way a patient’s immunosuppressive 
medication levels are not erroneously reduced in someone who is indeed at a greater 
risk for rejection. 
Diagnostic statistics were run for all models to evaluate outliers (standardized residuals) 
and influential cases (Cook’s distance, leverage/hat values, and standardized DFBeta).  
In order to confirm that the assumptions of the logistic regression model were not 
violated, each model was checked for linearity, independence of errors, and 
multicollinearity.  The assumption of linearity was tested by looking at whether the 
interaction term between the predictor and its log transformation was significant.  Using 
the deviance statistic, the assumption of independence was evaluated for over-
dispersion and under-dispersion.  Multicollinearity was checked with tolerance and 
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variable inflation factor (VIF) statistics, eigenvalues, condition indexes, and variance 
proportions.    
Each predictor variable and its interactions were assessed for contribution to the logistic 
regression model using the Wald statistic and likelihood ratio.  Effect size for each 
predictor was measured using the odds ratio or coefficient.  As is common in small 
samples, the Wald chi-square did not match with the overall test of the model.   
Interactions were not significant and were excluded from the models.  However, all 
variables have been widely accepted as clinically important in the transplant community.  
Therefore, coefficients were calculated for each variable regardless of the significance 
of the Wald statistic.  Each full model (all variables entered) for the statewide population 
was compared to the corresponding full model for the TNUK population.  This allowed 
us to compare the full model across both population sets and different measures of 
outcome for the traditional scoring system.  The best fit models, as determined by 
backward stepwise logistic regression are also listed with each full model for traditional 
and expanded scoring.   
Summary List of Model Comparisons:   
• Statewide—1 year—Function/Non-Function—Traditional   
o TNUK—1 year—Function/Non-Function—Traditional  
• Statewide—3 year—Function/Non-Function—Traditional   
o TNUK—3 year—Function/Non-Function—Traditional  
• TNUK—1 year—Function/Non-Function—Traditional    
o TNUK—1 year—Function/Non-Function—Expanded  
• TNUK—3 year—Function/Non-Function—Traditional    
o TNUK—3 year—Function/Non-Function—Expanded 
• TNUK—12 mo Creatinine—Traditional    
o TNUK—12mo Creatinine—Expanded  
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CHAPTER IV:  RESULTS AND DISCUSSION 
 
Univariate Analysis 
Univariate analysis of the statewide population indicated that only two predictor 
variables in the traditional scoring system model were statistically significant for the 1 
year and 3 years outcomes (Table 4. See APPENDIX ).  Univariate analysis indicated 
that donor grafts from women were significantly more likely to be non-functioning at 1 
year (53%) than were donor grafts from men (47%), x(1, N = 694) = 9.94, p < 0.05) 
(Table 5. see APPENDIX).  However, at 3 years post-transplant, kidney grafts that were 
mismatched for the DRDQ loci were more likely to be non-functioning (82%) than were 
DRDQ matched grafts (18%), x(1, N = 455) = 4.41, p < 0.05) (Table 6. See 
APPENDIX).   
Univariate analysis of the TNUK population data for both the traditional scoring system 
variables and the expanded scoring system variables are listed in Table 7 (See 
APPENDIX).  No significant associations were found between 1 year outcome and the 
predictor variables for the TNUK population.  However, evaluation of the likelihood 
ratios (exact 2-tailed) of the TNUK population revealed a significant relationship 
between PRA, Λ (3, N = 62) = 6.78, p < 0.05) and KIR matching, Λ (1, N = 62) = 7.01, p 
< 0.05) with function at 3 years.  Of the 58 functioning grafts at the 3 years follow-up, 
72% had a PRA between 0-19% (Table 8. See APPENDIX) and 60% of the 58 grafts 
had excess inhibitory KIR receptors (Table 9. see APPENDIX ).  None of the patients 
with excess inhibitory KIR receptors had a non-functioning graft at 3 years. 
Since sCD30 levels, recipient age, donor age, and 12 month creatinine levels were not 
normally distributed (Shapiro-Wilk test p < 0.05), Kendall’s tau (2-tailed) was used to 
assess their relationships.  Recipient age was significantly correlated to 12 month 
creatinine level in the TNUK population, τ = - 0.32, p < 0.05 (Table 10. see APPENDIX).  
Creatinine levels at 12 months post-transplant ranged from 0.82-2.50 mg/dL with a 
mean of 1.46 mg/dL (± 0.43 mg/dL).  Creatinine levels were analyzed for each group 
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within the variables using Mann-Whitney and Jonckheere-Terpstra Test (2-tailed) 
(Tables 11-12. see APPENDIX).  Creatinine levels in male recipients (1.53 ± 0.45 
mg/dL) were significantly different from female recipients (1.30 ± 0.35 mg/dL), U = 
276.00, z = -2.03, p < 0.05, r = - 0.26 (Table 13. See APPENDIX).  Creatinine levels 
were also significantly different for patients with a DRDQ mismatch (1.54 ± 0.44 mg/dL) 
than for those with a DRDQ matched kidney (1.21 ± 0.31 mg/dL), U = 182.50, z = -2.81, 
p < 0.05, r = - 0.36 (Table 13. See APPENDIX).  Creatinine levels were higher on 
average for patients with MICA Abs present (1.73 ± 0.46 mg/dL) than levels were in 
those who did not have MICA Abs (1.42 ± 0.41 mg/dL), U = 336.00, z = 1.96, p = 0.050, 
r = 0.25) (Table 13. See APPENDIX).     
 
Model Validity and Reliability 
While the occurrence of kidney graft rejection is not a rare event, it was limited in the 
populations.  For the state of Tennessee, 10% had a non-functioning graft at 1 year and 
12% had a non-functioning graft at 3 years.  The TNUK population was even more 
limited with 3% non-functioning at 1 year and 6% non-functioning at 3 years.  These 
limited occurrences cause sampling distribution errors.  This lack of variation in the 
dependent variable made it difficult to estimate a model.   Summaries of the model 
goodness of fit (Table 14) and predictive abilities (Table 15) are given in the Appendix. 
 
Goodness of Fit 
The traditional scoring model 1 (full model) for non-functioning at 1 year, using data 
from the statewide population, was not statistically better at predicting outcome than the 
model with only the constant included (Table 14. See APPENDIX).  However, donor 
gender was a significant variable (Table 16. See APPENDIX ), which was in agreement 
with the likelihood ratio statistic from the univariate analysis.  Backward stepwise 
selection produced a significant model (model 2), but of the three predictor variables in 
the model, only donor gender was significant (Table 17. See APPENDIX ) 
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Using the statewide population data, neither the traditional scoring model 3(full model) 
for non-functioning at 3 years (Table 18. See APPENDIX ), nor the backward stepwise 
model 4 (Table 19. See APPENDIX) contained any statistically significant predictor 
variables.  While DRDQ matching was significant in univariate analysis, it did not reach 
statistical significance in either model.  The full model 3 (full model) was not better at 
predicting the outcome than the model with only the constant included (Table 14. See 
APPENDIX).  Backward stepwise selection (model 4) did produce a significant model 
overall which included DRDQ matching (Table 19. See APPENDIX).   
For the TNUK population, neither model 5 nor model 6 for outcome at 1 year was 
statistically significant, nor did they contain any significant predictor variables (Tables20-
21. See APPENDIX).  This agreed with the univariate analysis for 1 year outcome of the 
TNUK population. 
The traditional scoring model 7 (full model) for non-functioning at 3 years, using data 
from the TNUK, was not statistically better at predicting outcome than the model with 
only the constant included (Table 14. See APPENDIX).  It did, however, contain one 
significant predictor variable, PRA 20-30%, which was in agreement with the univariate 
analysis of 3 year outcome (Table 22. See APPENDIX).  The backward stepwise model 
8 contained the PRA 20-30% p < 0.05, as well as the other PRA categories and DRDQ 
matching p = ns (Table 23. See APPENDIX).  
The expanded scoring model 9 (full model) for outcome at 1 year (TNUK population) 
was not statistically better for prediction of outcome than the constant only model (Table 
14. See APPENDIX) and did not contain any significant predictor variables (Table 24. 
See APPENDIX ).  The backward stepwise model 10, while significant (Table 14. See 
APPENDIX), did not contain any significant predictor variables (Table 25. See 
APPENDIX ).  Again, these models agreed with univariate analysis of TNUK data at 1 
year outcomes. 
Both the expanded scoring models for outcome at 3 years (TNUK population) were 
statistically significant (Table 14. See APPENDIX).  Neither the full model nor the 
backward stepwise model contained significant predictor variables (Table 26-27. See 
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APPENDIX).  This is in contrast to the 3 year TNUK univariate analysis that indicated 
KIR matching and PRA were significant. 
 
Predictive Ability 
All models had 100% sensitivity, except for model 8 TNUK backward stepwise standard 
scoring, which also had the highest false negative rate (Table 15. See APPENDIX).  All 
TNUK expanded models (models 9-12) had 100% sensitivity and 100% specificity.  
These models also had 100% positive predictive values and 100% negative predictive 
values.  They also had 0 % false positive and false negative rates.  It is most interesting 
that of these models, the 3 year outcome models (models 11-12) were statistically 
significant and had the highest chi-square values.  They also had the highest Cox & 
Snell R Square and Nagelkerke R Square values, as well as the lowest -2LL values.   
All standard models (statewide and TNUK) had false positive rates greater than 1.6% 
and specificities of 0% or 50%. 
 
Summary 
These models were designed to help clinicians adjust immunosuppressant levels 
(maintain lower therapeutic levels for patients’ with lower risk); therefore, we focused on 
the following criteria when evaluating each model: chi-square goodness of fit, R square, 
-2LL, sensitivity, negative predictive value, and false negative rate.  Using these criteria 
to evaluate the models, we ranked the significant models (p < 0.05), from most clinical 
relevance to least relevant.  The last three models were so poor, that they were ranked 
based on R square and -2LL. 
Model 12: TNUK expanded 3 yr (stepwise) x(11) = 29.66, p < 0.01, R  = 0.38, R  = 
1.00, -2LL = 0, 100% sensitivity, 100% NPV, 0%FN. 
Model 11: TNUK expanded 3 yr (full) x(15) = 29.66, p < 0.05, R  = 0.38, R  = 1.00, -
2LL = 0, 100% sensitivity, 100% NPV, 0%FN. 
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Model 10: TNUK expanded 1 yr (stepwise) x(7) = 17.80, p < 0.05, R  = 0.24, R  = 
1.00, -2LL = 0, 100% sensitivity, 100% NPV, 0%FN. 
Model 8: TNUK standard 3 yr (stepwise) x(4) = 10.15, p < 0.05, R  = 0.15, R  = 0.40, 
-2LL = 19.51, 95.6% sensitivity, 50% NPV, 50%FN. 
Model 2: State standard 1yr (stepwise) x(3) = 16.80, p < 0.01, R  = 0.02,  R  = 0.05, -
2LL = 427.62, 100% sensitivity, NPV—unable to calculate, FN—unable to calculate. 
Model 4: State standard 3 yr (stepwise) x(1) = 4.11, p < 0.05, R  = 0.01, R  = 0.02,   -
2LL = 417.88, 100% sensitivity, NPV—unable to calculate, FN—unable to calculate. 
In consideration of overall model statistics, the TNUK expanded models for outcome at 
3 years (models 11-12) are the most helpful in prediction of graft loss.  These models 
were not subject to undue influence by individual cases (Cook’s, Leverage, 
standardized DFBeta), unacceptable levels of error (standardized residuals), or 
multicollinearity (VIF, tolerance, etc.).  However, over-dispersion was present in both 
models (deviance statistic).  This was most likely due to the poor variability in the 
outcome probabilities of the TNUK population or a result of other data complexities that 
are not understood.  Unsystematic variation in the TNUK population (e.g. different types 
and dosage of immunosuppressant drugs) cannot be controlled for in such a limited 
population, therefore, no over-dispersion correction was performed.  It is interesting that 
the backward stepwise selection Model 12 retains the proposed expanded testing 
variables, and drops the traditionally accepted factors of recipient gender and ethnicity, 
donor age, and HLA matching of AB and DRDQ.   
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CHAPTER V:  CONCLUSIONS  
 
Conclusions, Implications, and Recommendations 
Clinicians lack appropriate non-invasive methods to be able to predict, diagnose, and 
reduce the risk of rejection in the years following kidney transplantation.  Protocol 
biopsies and monitoring of serum creatinine levels are the most widely utilized 
approaches to monitoring graft function after transplant.  However, biopsies come with 
some risks, as do all invasive procedures, and monitoring serum creatinine does not 
provide enough forewarning of rejection.   Instead, we recommend the use of a post-
transplant monitoring tool as an indirect approach for increasing the number of available 
kidneys by predicting risk of kidney graft outcome and  for use in adjustment of post-
transplant immunosuppression treatment. 
Utilizing immunologic factors that were available to clinicians across the United States, 
we present a model for predicting graft function at 3 years post-transplant. This model 
includes the traditional factors, as well as additional factors, which other studies have 
indicated as predictors for renal allograft function. Traditional factors (HLA matching for 
each donor and recipient pair, pre-transplant PRA levels, and standard population 
demographics) and supplementary factors (MICA matching between donor and 
recipient, KIRmatching between donor and recipient, identification of MICA antibodies, 
and sCD30 level) were evaluated for incorporation into the model.  Testing kits for the 
additional factors are available through multiple vendors, and are simple to use.  
Therefore, other centers should be able to incorporating these additional tests into their 
routine testing for donors and recipients and allow the center to develop a similar 
expanded scoring model for post-transplant monitoring of renal allografts.  To our 
knowledge, this is the first time a single model has been proposed utilizing MICA, KIR, 
sCD30, and traditional HLA testing on the same individual study population. 
Using multi-center data from adult recipients of SCD kidneys, we were able to construct 
models, containing the traditional factors only, for prediction of outcome at 1 year and 3 
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years post-transplant.  Using single-center data from adult recipients of SCD kidneys, 
we developed comparison models containing traditional factors only, as well as, 
expanded models containing the new suggested variables for prediction of outcome 
post-transplant.  These additional variables, when incorporated into the expanded 
models provided greater positive predictive values, greater negative predictive values, 
and lower false negative rates for graft outcome at 1 year and at 3 years post-transplant 
than the models utilizing traditional factors only 
We suggest that either of the expanded models (models #11 and #12) for predicting 
kidney graft outcome at 3 years would be appropriate for use by clinicians in evaluating 
adjustment of post-transplant immunosuppression regimens.  However, these models 
should be validated with a larger data set and evaluated for utility in the course of 
various immunosuppressant drugs before implementation in the clinic. These models 
contain both the traditionally accepted risk factors for graft rejection as well as the new 
proposed expanded testing variables.  Both models were statistically significant, with 
excellent specificity, false negative rate, and negative predictive value.  Individual 
variables and interaction terms were not significant in these logistic regression models, 
but univariate analysis indicated that 3 year outcomes may be related to KIR matching 
and percent PRA.  While we are pleased that our 3 year rejection rates at TNUK and 
throughout Tennessee are low, it does create obstacles for research.  The lack of 
variation in the outcome variables (because of the low percent of rejection in the TNUK 
population) created difficulties in developing appropriate models, and is the most likely 
explanation for the inability of this study to obtain similar significant findings observed in 
other studies.  
The 3 year expanded model (#12 backward-stepwise) is valid for the TNUK population, 
and may not reflect other centers’ population demographics and compliance, 
immunosuppressive protocols, rescue therapy for rejection episodes that do not result in 
return to dialysis, and numerous other factors that could influence a patient’s 
immunologic status.  It is interesting that removal of the traditional factors of HLA AB 
and DRDQ typing, recipient gender and ethnicity, and donor age from full 3 year 
expanded model results in the statistically significant model 12.  However, it would be 
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unwise to disregard such important factors in transplant outcomes.  We encourage 
other transplant centers to participate in additional testing of sCD30, MICA and KIR, and 
attempt to cross-validate this model or develop similar models utilizing a larger data set.  
The TNUK population was not reflective of the statewide population, and therefore, 
comparisons between TNUK models and statewide population models could not be 
made.  One of the most obvious differences in the statewide population and the TNUK 
population was the ethnicity of recipients and donors.  TNUK has a predominantly 
Caucasian donor population and Caucasian recipient population, whereas statewide, 
the recipient ethnic groups are more even and the percentage of African American 
donors is twice as high as that of TNUK.  We plan to investigate this and other socio-
economic disparities across the state in the future.  Because the two study populations 
were so dissimilar in their basic demographics, traditional TNUK models could not be 
compared to traditional statewide models, and subsequent conclusions regarding the 
efficacy of the TNUK expanded models could not be drawn for the statewide population.  
We advocate the use of the 3 year expanded model (model #12) as a secondary, non-
invasive tool for use by TNUK clinicians for prediction of renal allograft outcome.  We 
predict that a future investigation, utilizing various immunosuppression regimens, will 
contribute to the validity of this model as a “tailor-made” approach to graft maintenance.   
Further study is needed to determine the lack of significant predictors in the model.  
Samples should continue to be collected both pre- and post-transplant for validation of 
this 3 year model, for monitoring of sCD30 level changes, PRA changes, and MICA 
antibody changes post-transplant, and for future development of a 5 year outcome 
model.  Continued collection of DNA and serum samples will provide a greater pool for 
subsequent studies which may expound upon our understanding of each variable’s 
veritable role in graft outcome.   
While these models were designed to be based on immunologic risk factors, additional 
risks may develop (due to patient’s or clinician’s actions) which are not encompassed in 
the models and may shift the patient from being in the non-rejection to the rejection 
categorization.  Social and economic factors contribute considerably to an individual’s 
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collective health state.  It is unrealistic to expect a single model to incorporate every 
minute aspect of each individual’s immune status.  Nevertheless, this general model of 
important transplant factors is a propitious tool in predicting risk for individuals in the 
TNUK population.  This 3 year expanded model solely addresses immunologic factors, 
not ethical considerations, and is not intended for use as an allocation algorithm, but 
rather a tool to aid clinicians in the post-transplant care management of their patients. 
Creatinine level is an established measure of graft function and is widely used to 
monitor effectiveness of treatment for rejection episodes.  However, using creatinine 
levels alone to monitor grafts is unwise because elevated serum creatinine occurs after 
damage to the kidney allograft is nearly established.  Our univariate analysis of factors 
and the 1 year function outcome in the TNUK population did not reveal a significant 
relationship. However, analysis of 12 month creatinine and these factors suggests that 
some factors warrant further consideration when formulating a predictive model.  Male 
recipients, patients with a DRDQ mismatch, patients with MICA antibodies present, and 
surprisingly, younger recipients, had higher 12 month creatinine levels than their 
counterparts.  These correlations agree with other studies linking male recipients, 
DRDQ mismatching, and presence of MICA antibodies to poorer graft outcome 
(reflective here as increased creatinine levels).  It is unclear why younger recipients had 
significantly higher creatinine levels.  Perhaps it is simply because the TNUK recipients 
were on average older (µ = 54.0 ± 12.6 years) than the statewide population (µ = 49.4 ± 
12.0 years), and that “younger” recipients in the TNUK population are not as “young” as 
those in the statewide population.  Further study is need to determine if higher 
creatinine levels in younger recipients were the result of greater metabolic demands in 
younger persons, non-compliance, or another factor not encompassed by this study 
such as extended cold-times.  All of the 12 month creatinine correlations should be 
evaluated with caution, as they are reflective of the TNUK study population.  It is not 
advisable to extrapolate these correlations to other populations, but rather they lay 
foundation for investigation of creatinine levels in subsequent case-controlled studies. 
This study provided a limited opportunity for recipient-donor pair to pair comparisons.  
We did examine the 6 cases with failed grafts and contrasted them with functioning 
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cases matched for recipient age, donor age, recipient ethnicity, donor ethnicity, recipient 
gender, donor gender, and PRA level in various combinations.  For example, a 47 year 
old female Caucasian recipient with greater than 80% PRA who received a kidney 
allograft from a 35 year old female Caucasian recipient had a non-functioning graft at 3 
years post transplant.  Compare this to a 47 year old female Caucasian recipient with 
greater than 80% PRA who received a kidney allograft from a 28 year old female 
Caucasian who still had a functioning graft at 3 years post-transplant.  Based on the 
data we collected, the only difference in these cases was that the functioning graft pair 
was a match for AB, DRDQ, and MICA.  Other comparisons of donor-recipient pairs 
have indicated that patients with MICA Abs and excess inhibitory KIR were more likely 
to have functioning grafts at 3 years.  In fact, none of the patients with excess inhibitory 
KIR had a non-functioning graft at 1 year or 3 years.  While these “findings” are 
intriguing and require further consideration, the predictor variables were not individually 
statistically significant within the model.  Just as higher average creatinine levels were 
observed in patients with certain characteristics in the TNUK population, these case-
wise evaluations do not provide a definitive connection between these variables, as they 
too are limited by the size of the study population.  Individual immune statuses differ 
given a variety of biological, environmental, social, and economic factors, and have 
diverse responses to immunological challenge.  Therefore to make any valid claims 
regarding a valid relationship between these characteristics at the population level, we 
would need to examine an immense number of recipient-donor pairs. 
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Table 1:  Tennessee Statewide Study Population 
Characteristic  Number of Recipients 
 (% of Total Population) 
Number of Donors  
(% of Total Population) 
Gender   
     Male 465 (67%) 446 (64%) 
     Female 229 (33%) 248 (36%) 
Ethnicity/Race   
     Caucasian/ White 389 (56%) 587 (85%) 
     African American/ Black 305(44%) 107 (15%) 
Mean Age (Standard 
Deviation) 
49.4 (± 12.0 years) 32.0 (± 14.6 years) 
 
 
Table 2:  TNUK Study Population 
Characteristic  Number of Recipients  
(% of Total Population) 
Number of Donors  
(% of Total Population) 
Gender   
     Male   45 (70%)   39 (61%) 
     Female   19 (30%)   25 (39%) 
Ethnicity/Race    
     Caucasian/ White   61 (95%)   59 (92 %) 
     African American/ Black     3 (5%)     5 (8%) 
Mean Age (Standard 
Deviation) 
54 (± 12.6 years) 34 (± 14.2 years) 
 
 
Table 3:  Population Outcome Comparison 
Population  Year of 
Measure 
Number of Functioning 
Grafts (% of Total 
Population) 
Number of Non-Functioning 
Grafts (% of Total 
Population) 
Tennessee 1 year 624 (90%) 70 (10%) 
Tennessee 3 years 373 (82%) 82 (18%) 
TNUK 1 year 62 (97%) 2 (3%) 
TNUK 3 years 58 (94%)  4 (6%) 
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Table 4:  Statewide Population:  Univariate Analysis of Relationship Between 
Categorical Predictor Variables and Graft Function at 1 and 3 years Post-
Transplant 
Predictor 
Variable 
Year Outcome 
Measured (Non-
Functioning)  
Pearson  
chi-squared 
(x²) 
Likelihood 
Ratio  (Λ) 
Cramer’s V Exact Sig. 
(2-sided) 
PRA 1 year 2.141* 1.923 0.056 0.166 
PRA 3 years 2.008* 1.895 0.067 0.150 
Recipient 
Gender 
1 year 3.423 3.300 0.070 0.081 
Recipient 
Gender 
3 years 0.214 0.212 0.022 0.698 
Recipient 
Ethnicity 
1 year 1.158 1.150 0.041 0.310 
Recipient 
Ethnicity 
3 years 0.669 0.669 0.038 0.464 
DRDQ loci  1 year 3.218 3.460 0.068 0.090 
DRDQ loci 3 years 4.414 4.721 0.098 0.041 
AB loci 1 year 0.952 1.010 0.037 0.341 
AB loci 3 years 0.895 0.947 0.044 0.389 
Donor 
Gender 
1 year 9.939 9.530 0.120 0.002 
Donor 
Gender 
3 years 1.468 1.448 0.057 0.258 
Donor 
Ethnicity 
1 year 0.178 0.173 0.016 0.727 
Donor 
Ethnicity 
3 years 0.249 0.255 0.023 0.630 
Note: * more than 20% of cells had expected counts less than 5.  Chi-square not valid. 
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Table 5: Frequency of Graft Outcomes at 1 year for Donor Gender (Statewide) 
 
Donor Gender 
Total Male Female 
Functioning at 1 Year Count 413 211 624 
Expected Count 401.0 223.0 624.0 
% within Function 1 yr 66.2% 33.8% 100.0% 
% within Donor 
Gender 
92.6% 85.1% 89.9% 
% of Total 59.5% 30.4% 89.9% 
Std. Residual 0.6 -0.8  
 Non-functioning at 1 Year Count 33 37 70 
Expected Count 45.0 25.0 70.0 
% within Function 1 yr 47.1% 52.9% 100.0% 
% within Donor 
Gender 
7.4% 14.9% 10.1% 
% of Total 4.8% 5.3% 10.1% 
Std. Residual -1.8 2.4  
Total Count 446 248 694 
Expected Count 446.0 248.0 694.0 
% within Function 1 yr 64.3% 35.7% 100.0% 
% within Donor 
Gender 
100.0% 100.0% 100.0% 
% of Total 64.3% 35.7% 100.0% 
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Table 6: Frequency of Graft Outcomes at 3 years for DRDQ matching (Statewide) 
 
DRDQ 
Total mismatch match 
Functioning at 3 
years 
Count 262 111 373 
Expected Count 269.7 103.3 373.0 
% within Function 3 yr 70.2% 29.8% 100.0% 
% within DRDQ 79.6% 88.1% 82.0% 
% of Total 57.6% 24.4% 82.0% 
Std. Residual -0.5 0.8  
Non-functioning at 3 
years 
Count 67 15 82 
Expected Count 59.3 22.7 82.0 
% within Function 3 yr 81.7% 18.3% 100.0% 
% within DRDQ 20.4% 11.9% 18.0% 
% of Total 14.7% 3.3% 18.0% 
Std. Residual 1.0 -1.6  
Total Count 329 126 455 
Expected Count 329.0 126.0 455.0 
% within Function 3 yr 72.3% 27.7% 100.0% 
% within DRDQ 100.0% 100.0% 100.0% 
% of Total 72.3% 27.7% 100.0% 
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Table 7:  TNUK population:  Univariate Analysis of Relationship Between 
Categorical Predictor Variables and Graft Function at 1 and 3 years Post-
Transplant 
 
Predictor 
Variable 
 
Year Outcome 
Measured (Non-
Functioning) 
 
Pearson  
chi-squared 
(x²) 
 
Likelihood 
Ratio (Λ) 
 
 
Cramer’s V 
 
Exact Sig. 
(2-sided) 
PRA 1 year 4.175* 2.802a 0.255 0.141 
PRA 3 years 9.522* 6.784b 0.392 0.010 
Recipient 
Gender 
1 year 0.872* 1.436 0.117 0.576 
Recipient 
Gender 
3 years 0.034* 0.035 0.023 1.000 
Recipient 
Ethnicity 
1 year 0.102* 0.195 0.040 1.000 
Recipient 
Ethnicity 
3 years 0.217* 0.411 0.059 1.000 
DRDQ loci  1 year 0.632* 1.088c 0.099 1.000 
DRDQ loci 3 years 1.365* 2.303d 0.148 0.564 
AB loci 1 year 0.295* 0.543 0.068 1.000 
AB loci 3 years 0.633* 1.145 0.101 0.644 
Donor 
Gender 
1 year 1.323* 2.022 0.144 0.516 
Donor 
Gender 
3 years 0.417* 0.442 0.082 0.642 
Donor 
Ethnicity 
1 year 5.102* 2.685 0.282 0.151 
Donor 
Ethnicity 
3 years 1.654* 1.153 0.163 0.292 
MICA Abs 1 year 0.338* 0.617 0.073 1.000 
MICA Abs 3 years 0.379* 0.327 0.078 1.000 
KIR 1 year 2.654* 3.390 0.204 0.187 
KIR 3 years 5.543* 7.011 0.299 0.031 
MICA 
matching 
1 year 0.277* 0.260 0.066 1.000 
MICA 
matching 
3 years 0.150* 0.158 0.049 1.000 
Note: Exact Sig. (2-sided): a) p = 0.149; b) p = 0.012; c) p =0.635; d) p = 0.361; * more 
than 20% of cells had expected counts less than 5.  Chi-square not valid. 
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Table 8:  Frequency of Graft Outcomes at 3 years for PRA (TNUK) 
 PRA 0-
19% 
PRA 
20-
39% 
PRA 
40-
79% 
PRA > 
80% Total 
Functioning at 3 
years 
Count 42 4 6 6 58 
Expected Count 40.2 5.6 5.6 6.5 58.0 
% within Function 3 yr 72.4% 6.9% 10.3% 10.3% 100.0% 
% within PRA 97.7% 66.7% 100.0% 85.7% 93.5% 
% of Total 67.7% 6.5% 9.7% 9.7% 93.5% 
Std. Residual 0.3 -0.7 0.2 -0.2  
Non-functioning 
at 3 years 
Count 1 2 0 1 4 
Expected Count 2.8 0.4 0.4 0.5 4.0 
% within Function 3 yr 25.0% 50.0% 0.0% 25.0% 100.0% 
% within PRA 2.3% 33.3% 0.0% 14.3% 6.5% 
% of Total 1.6% 3.2% 0.0% 1.6% 6.5% 
Std. Residual -1.1 2.6 -0.6 0.8  
Total Count 43 6 6 7 62 
Expected Count 43.0 6.0 6.0 7.0 62.0 
% within Function 3 yr 69.4% 9.7% 9.7% 11.3% 100.0% 
% within PRA 100.0% 100.0% 100.0% 100.0% 100.0% 
% of Total 69.4% 9.7% 9.7% 11.3% 100.0% 
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Table 9: Frequency of Graft Outcomes at 3 years for KIR (TNUK) 
 
KIR 
Total Balanced 
Excess 
Inhibitory 
Functioning at 3 
years 
Count 23 35 58 
Expected Count 25.3 32.7 58.0 
% within Function 3 yr 39.7% 60.3% 100.0% 
% within KIR 85.2% 100.0% 93.5% 
% of Total 37.1% 56.5% 93.5% 
Std. Residual -0.4 0.4  
Non-functioning 
at 3 years 
 
Count 4 0 4 
Expected Count 1.7 2.3 4.0 
% within Function 3 yr 100.0% 0.0% 100.0% 
% within KIR 14.8% 0.0% 6.5% 
% of Total 6.5% 0.0% 6.5% 
Std. Residual 1.7 -1.5  
Total Count 27 35 62 
Expected Count 27.0 35.0 62.0 
% within Function 3 yr 43.5% 56.5% 100.0% 
% within KIR 100.0% 100.0% 100.0% 
% of Total 43.5% 56.5% 100.0% 
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Table 10:  TNUK population:  Correlation of 12 month Creatinine Level with 
Soluble CD30 level, Recipient Age, and Donor Age (Kendall’s tau test) 
 
sCD30 
Recipient 
Age 
Donor  
Age 
12 mo 
Creatinine 
 sCD30 Correlation Coefficient 1.000 -0.110 -0.016 -0.029 
Sig. (2-tailed) . 0.208 0.857 0.746 
N 64 64 64 62 
Recipient Age Correlation Coefficient -0.110 1.000 0.019 -0.216* 
Sig. (2-tailed) 0.208 . 0.830 0.018 
N 64 64 64 62 
Donor Age Correlation Coefficient -0.016 0.019 1.000 0.173 
Sig. (2-tailed) 0.857 0.830 . 0.056 
N 64 64 64 62 
12 mo. 
Creatinine 
Correlation Coefficient -0.029 -0.216* 0.173 1.000 
Sig. (2-tailed) 0.746 0.018 0.056 . 
N 62 62 62 62 
Note: * Correlation is significant at the 0.05 level (2-tailed). 
 
 
 
Table 11:  TNUK population:  Comparison of 12 month Creatinine Levels Across 
Different Categories of Nominal Variables (Mann-Whitney and Kolmogorov-
Smirnov Z Tests)  
Grouping 
Variable 
Mann-
Whitney U  
Mann-Whitney 
U Sig. 
Kolmogorov-
Smirnov Test  
Kolmogorov-
Smirnov Sig. 
PRA NA NA NA NA 
Recipient Gender 276.00 0.042* 1.00 0.266 
Recipient Ethnicity 91.00 0.934 0.54 0.929 
DRDQ loci  182.50 0.005* 1.24 0.091 
AB loci  165.00 0.282 0.84 0.476 
Donor Gender 480.00 0.801 0.61 0.857 
Donor Ethnicity 122.00 0.863 0.72 0.683 
MICA Abs  336.00 0.050 1.00 0.264 
KIR  417.00 0.465 0.75 0.632 
MICA matching 507.50 0.186 0.75 0.636 
Note:  *Significant at the 0.05 level (2-tailed). 
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Table 12: TNUK population:  Comparison of 12 month Creatinine Levels Across 
Different Categories of Nominal Variables (Jonckheere-Terpstra and Kruskal-
Wallis Tests) 
Grouping Variable Jonckheere-
Terpstra Test 
(standardized) 
Jonckheere-
Terpstra Sig. 
Kruskal-Wallis 
Test 
Kruskal-
Wallis Sig. 
PRA -0.39 0.742 4.26 0.235 
Recipient Gender -2.03 0.042* 4.13 0.042* 
Recipient Ethnicity 0.08 0.934 0.01 0.934 
DRDQ loci  -2.81 0.005* 7.88 0.005* 
AB loci  -1.08 0.282 1.16 0.282 
Donor Gender 0.25 0.801 0.06 0.801 
Donor Ethnicity 0.17 0.863 0.03 0.863 
MICA Abs  1.96 0.050 3.83 0.050 
KIR  -0.73 0.465 0.53 0.465 
MICA matching 1.32 0.186 1.75 0.186 
Note:  *Significant at the 0.05 level (2-tailed). 
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Table 13:  Twelve Month Creatinine Levels for Each Category of Nominal 
Variables 
 
Predictor Variable/ Group 
Number of 
Patients in 
Group (n) 
Mean 
Creatinine 
level (mg/dL) 
 
SD 
 
95% C.I. 
PRA 0-19% 44 1.45 0.39 1.33-1.57 
PRA 20-39% 5 1.80 0.61 1.04-2.56 
PRA 40-79% 6 1.55 0.53 0.99-2.11 
PRA > 80% 7 1.23 0.37 0.88-1.58 
Male Recipient 43 1.53 0.45 1.40-1.67 
Female Recipient 19 1.30 0.35 1.13-1.46 
Caucasian Recipient 59 1.46 0.44 1.35-1.58 
African American Recipient 3 1.43 0.29 0.72-2.15 
DRDQ mismatch 47 1.54 0.44 1.41-1.67 
DRDQ match 15 1.21 0.31 1.04-1.38 
AB mismatch 54 1.49 0.43 1.37-1.60 
AB match 8 1.30 0.40 0.97-1.64 
MICA Abs absent 53 1.42 0.41 1.30-1.53 
MICA Abs present 9 1.73 0.46 1.38-2.09 
KIR balanced 26 1.54 0.52 1.33-1.74 
KIR inhibitory 36 1.41 0.35 1.29-1.53 
Male Donor 37 1.45 0.43 1.31-1.59 
Female Donor 25 1.48 0.44 1.30-1.66 
Caucasian Donor 58 1.46 0.44 1.35-1.59 
African American Donor 4 1.45 0.31 0.96-1.94 
MICA mismatch 42 1.42 0.42 1.29-1.55 
MICA match 20 1.56 0.46 1.34-1.77 
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Table 14: Model Goodness of Fit Summary 
Model Model 
df   
Model 
Chi-
square 
Model 
Sig 
-2 Log 
likelihood 
Cox & 
Snell R 
Square 
Nagelkerke 
R Square 
1 11 19.159 0.058 425.252 0.027 0.058 
2 3 16.796 0.001** 427.616 0.024 0.051 
3 11 9.174 0.606 412.813 0.020 0.033 
4  1 4.105 0.043** 417.882 0.009 0.015 
5 11 8.689 0.651 9.111 0.127 0.523 
6 1 -2.658 0.103 17.800 0.000 0.000 
7 11 13.094 0.287 16.569 0.190 0.501 
8 4 10.151 0.038** 19.512 0.151 0.397 
9 15 17.800 0.273 0.000 0.243 1.000 
10 7 17.800 0.013** 0.000 0.243 1.000 
11 15 29.663 0.013** 0.000 0.380 1.000 
12 11 29.663 0.002** 0.000 0.380 1.000 
Note:  **Significant at the 0.05 level (2-tailed). 
 
 
Table 15:  Model Predictive Ability Summary 
Model Sensitivity 
% 
Specificity 
% 
Positive 
Predictive 
Value % 
Negative 
Predictive 
Value % 
False 
Positive 
Rate % 
False 
Negative 
Rate % 
1 100 0 90.2 NA** 9.8 NA** 
2 100 0 90.2 NA** 9.8 NA** 
3 100 0 82.3 NA** 17.7 NA** 
4 100 0 82.3 NA** 17.7 NA** 
5 100 50 98.4 100 1.6 0 
6 100 0 96.9 NA** 3.1 NA** 
7 100 50 96.7 100 3.3 0 
8 95.6 50 95.6 50 3.4 50 
9 100 100 100 100 0 0 
10 100 100 100 100 0 0 
11 100 100 100 100 0 0 
12 100 100 100 100 0 0 
Note: ** Unable to calculate.  Zero denominator. 
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Table 16:  Model 1:  Traditional Scoring Model (Full Model) for Non-Functioning at 
1 year.  Statewide Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for  
Odds Ratio 
Lower Upper 
PRA 1.480 3 0.687 
pra 20-39% 0.036 0.571 0.004 1 0.950 1.036 0.338 3.173 
pra 40-79% 0.469 0.410 1.311 1 0.252 1.599 0.716 3.568 
pra > 80% 0.289 0.519 0.310 1 0.578 1.335 0.483 3.692 
Recipient Age -0.002 0.011 0.019 1 0.890 0.998 0.977 1.021 
Recipient Female 0.421 0.278 2.295 1 0.130 1.523 0.884 2.625 
Recipient African 
American 
0.142 0.280 0.257 1 0.612 1.152 0.666 1.994 
DRDQ match -0.454 0.364 1.560 1 0.212 0.635 0.311 1.295 
AB match -0.177 0.414 0.182 1 0.670 0.838 0.372 1.886 
Donor Age 0.005 0.009 0.278 1 0.598 1.005 0.987 1.023 
Donor Female 0.817* 0.264 9.582 1 0.002 2.265 1.350 3.800 
Donor African American 0.186 0.356 0.273 1 0.601 1.205 0.599 2.422 
Constant -2.846* 0.700 16.512 1 0.000 0.058 
 R

= 0.03(Cox & Snell), 0.06(Nagelkerke).  Model x(11) = 19.16, p = 0.058. * p < 0.05  
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 17:  Model 2: Traditional Scoring Model (Backwards Stepwise) for Non-
Functioning at 1 year.  Statewide Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for 
Odds Ratio 
Lower Upper 
Recipient Female 0.480 0.264 3.314 1 0.069 1.616 0.964 2.709 
DRDQ match -0.558 0.325 2.952 1 0.086 0.572 0.303 1.082 
Donor Female 0.835 0.259 10.395 1 0.001 2.305 1.387 3.830 
Constant -2.629 0.223 139.149 1 0.000 0.072 
R

= 0.02(Cox & Snell), 0.05(Nagelkerke).  Model x(3) = 16.80, p = 0.001. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 18:  Model 3:  Traditional Scoring Model (Full Model) for Non-Functioning at 
3 years.  Statewide Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for  
Odds Ratio 
Lower Upper 
PRA  1.986 3 0.575 
pra 20-39% 0.252 0.542 0.216 1 0.642 1.287 0.445 3.723 
pra 40-79% 0.454 0.391 1.346 1 0.246 1.575 0.731 3.392 
pra > 80% 0.509 0.553 0.847 1 0.357 1.664 0.563 4.918 
Recipient Age 0.002 0.011 0.041 1 0.839 1.002 0.981 1.024 
Recipient Female 0.020 0.282 0.005 1 0.945 1.020 0.586 1.774 
Recipient African 
American 
0.165 0.271 0.371 1 0.542 1.180 0.693 2.007 
DRDQ match -0.604 0.362 2.783 1 0.095 0.547 0.269 1.111 
AB match -0.011 0.465 0.001 1 0.981 0.989 0.397 2.462 
Donor Age 0.005 0.009 0.342 1 0.559 1.005 0.988 1.023 
Donor Female 0.319 0.255 1.562 1 0.211 1.375 0.834 2.266 
Donor African American -0.156 0.360 0.187 1 0.665 0.856 0.423 1.732 
Constant -1.961* 0.681 8.293 1 0.004 0.141   
 R

= 0.02(Cox & Snell), 0.03(Nagelkerke).  Model x(11) = 9.17, p = 0.606. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 19:  Model 4:  Traditional Scoring Model (Backward Stepwise) for Non-
Functioning at 3 years.  Statewide Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for 
Odds Ratio 
Lower Upper 
DRDQ match  -0.598 0.308 3.772 1 0.052 0.550 0.300 1.006 
Constant -1.394* 0.139 101.197 1 0.000 0.248 
R

= 0.01(Cox & Snell), 0.02(Nagelkerke).  Model x(1) = 4.11, p = 0.043. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 20:  Model 5:  Traditional Scoring Model (Full Model) for Non-Functioning at 
1 year.  TNUK Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for  
Odds Ratio 
Lower Upper 
PRA   0.261 3 0.967    
pra 20-39% 0.963 1.884 0.261 1 0.609 2.619 0.065 105.212 
pra 40-79% -17.345 14036.550 0.000 1 0.999 0.000 0.000 . 
pra > 80% -16.206 12470.524 0.000 1 0.999 0.000 0.000 . 
Recipient Age -0.046 0.078 0.347 1 0.556 0.955 0.821 1.112 
Recipient Female -17.842 6939.659 0.000 1 0.998 0.000 0.000 . 
Recipient African 
American 
-18.347 21721.312 0.000 1 0.999 0.000 0.000 . 
DRDQ match -18.076 7839.011 0.000 1 0.998 0.000 0.000 . 
AB match -15.834 9733.612 0.000 1 0.999 0.000 0.000 . 
Donor Age 0.003 0.074 0.001 1 0.971 1.003 0.867 1.159 
Donor Female -17.072 6408.956 0.000 1 0.998 0.000 0.000 . 
Donor African 
American 
3.030 2.731 1.231 1 0.267 20.700 0.098 4367.788 
Constant -0.700 3.627 0.037 1 0.847 0.497   
R

= 0.13(Cox & Snell), 0.52(Nagelkerke).  Model x(11) = 8.69, p = 0.651. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 21:  Model 6:  Traditional Scoring Model (Backward Stepwise) for Non-
Functioning at 1 year.  TNUK Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for  
Odds Ratio 
Lower Upper 
 Constant -3.434* 0.718 22.848 1 0.000 0.032   
R

= 0.00(Cox & Snell), 0.00(Nagelkerke).  Model x(1) = -2.67, p = 0.103. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
 
 
 
 
Table 22:  Model 7:  Traditional Scoring Model (Full Model) for Non-Functioning at 
3 years.  TNUK Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for 
Odds Ratio 
Lower Upper 
PRA   5.971 3 0.113    
pra 20-39% 3.466* 1.425 5.913 1 0.015 32.000 1.959 522.756 
pra 40-79% -17.488 15867.422 0.000 1 0.999 0.000 0.000 . 
pra > 80% 2.079 1.510 1.895 1 0.169 8.000 0.414 154.429 
DRDQ match -19.301 9259.240 0.000 1 0.998 0.000 0.000 . 
Constant -3.466* 1.016 11.647 1 0.001 0.031   
 R= 0.19(Cox & Snell), 0.50(Nagelkerke).  Model x(11) = 13.1, p = 0.287. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 23:  Model 8:  Traditional Scoring Model (Backward Stepwise) for Non-
Functioning at 3 years.  TNUK Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for 
Odds Ratio 
Lower Upper 
PRA   5.971 3 0.113    
pra 20-39% 3.466* 1.425 5.913 1 0.015 32.000 1.959 522.756 
pra 40-79% -17.488 15867.422 0.000 1 0.999 0.000 0.000 . 
pra > 80% 2.079 1.510 1.895 1 0.169 8.000 0.414 154.429 
DRDQ match -19.301 9259.240 0.000 1 0.998 0.000 0.000 . 
Constant -3.466* 1.016 11.647 1 0.001 0.031   
  R= 0.15(Cox & Snell), 0.40(Nagelkerke).  Model x(4) = 10.2, p = 0.038. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 24:  Model 9:  Expanded Scoring Model (Full Model) for Non-Functioning at 
1 year.  TNUK Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for 
Odds Ratio 
Lower Upper 
PRA   0.000 3 1.000    
pra 20-39% -30.566 10480.299 0.000 1 0.998 0.000 0.000 . 
pra 40-79% -1.725 14071.026 0.000 1 1.000 0.178 0.000 . 
pra > 80% -25.760 25933285.283 0.000 1 1.000 0.000 0.000 . 
Recipient Age 0.227 1458.146 0.000 1 1.000 1.254 0.000 . 
Recipient 
Female 
-58.708 55179.497 0.000 1 0.999 0.000 0.000 . 
Recipient 
African 
American 
0.003 23068.797 0.000 1 1.000 1.003 0.000 . 
DRDQ match -2.975 14548.576 0.000 1 1.000 0.051 0.000 . 
AB match 53.322 25933175.662 0.000 1 1.000 1.44E23 0.000 . 
Donor Age -0.070 552.888 0.000 1 1.000 0.933 0.000 . 
Donor Female -35.155 12903.481 0.000 1 0.998 0.000 0.000 . 
Donor African 
American 
60.141 38418.279 0.000 1 0.999 1.32E26 0.000 . 
sCD30 0.002 13.211 0.000 1 1.000 1.002 0.000 1.76E11 
MICA abs 
present 
-1.882 11688.414 0.000 1 1.000 0.152 0.000 . 
KIR inhibitory -101.391 22567.298 0.000 1 0.996 0.000 0.000 . 
MICA match 35.629 16043.016 0.000 1 0.998 2.98E15 0.000 . 
Constant -30.459 83087.442 0.000 1 1.000 0.000   
R

= 0.24(Cox & Snell), 1.00(Nagelkerke).  Model x(15) = 17.8, p = 0.273. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 25:  Model 10:  Expanded Scoring Model (Backward Stepwise) for Non-
Functioning at 1 year.  TNUK Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for  
Odds Ratio 
Lower Upper 
Recipient Age 2.122 169.802 0.000 1 0.990 8.349 0.000 2.87E145 
Recipient Female -20.262 10431.010 0.000 1 0.998 0.000 0.000 . 
AB match  -40.176 14005.141 0.000 1 0.998 0.000 0.000 . 
Donor Female -48.844 5706.225 0.000 1 0.993 0.000 0.000 . 
Donor African 
American 
51.074 5060.138 0.000 1 0.992 1.52E22 0.000 . 
KIR inhibitory -129.173 9050.949 0.000 1 0.989 0.000 0.000 . 
MICA match 83.081 5882.552 0.000 1 0.989 1.21E36 0.000 . 
Constant -161.625 11885.134 0.000 1 0.989 0.000   
R

= 0.24(Cox & Snell), 1.00(Nagelkerke).  Model x(7) = 17.8, p = 0.013. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 26:  Model 11:  Expanded Scoring Model (Full Model) for Non-Functioning at 
3 years.  TNUK Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I. for   
Odds Ratio 
Lower       Upper 
PRA   0.001 3 1.000    
pra 20-39% 94.909 3192.120 0.001 1 0.976 1.65E41 0.000 . 
pra 40-79% 212.096 15978.321 0.000 1 0.989 1.29E92 0.000 . 
pra > 80% 253.078 7945.731 0.001 1 0.975 8.14E109 0.000 . 
Recipient 
Age 
7.983 273.906 0.001 1 0.977 2929.718 0.000 4.13E236 
Recipient 
Female 
39.662 3266.925 0.000 1 0.990 1.68E17 0.000 . 
Recipient 
African 
American 
282.608 21371.097 0.000 1 0.989 5.43E122 0.000 . 
DRDQ 
match 
-11.588 14000.454 0.000 1 0.999 0.000 0.000 . 
AB match -461.494 21563.194 0.000 1 0.983 0.000 0.000 . 
Donor Age -1.503 73.209 0.000 1 0.984 0.222 0.000 4.60E61 
Donor 
Female 
-118.864 4167.370 0.001 1 0.977 0.000 0.000 . 
Donor 
African 
American 
102.272 4001.572 0.001 1 0.980 2.61E44 0.000 . 
sCD30 -0.079 2.733 0.001 1 0.977 0.924 0.004 195.739 
MICA abs 
present 
-14.305 1884.269 0.000 1 0.994 0.000 0.000 . 
KIR 
inhibitory 
-325.162 10160.988 0.001 1 0.974 0.000 0.000 . 
MICA match 194.282 6411.107 0.001 1 0.976 2.38E84 0.000 . 
Constant -370.636 13479.376 0.001 1 0.978 0.000   
  R

= 0.38(Cox & Snell), 1.00(Nagelkerke).  Model x(15) = 29.7, p = 0.013. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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Table 27:  Model 12:  Expanded Scoring Model (Backward Stepwise) for Non-
Functioning at 3 years.  TNUK Population. 
 
B S.E. Wald df Sig. 
Odds 
Ratio 
95% C.I.for  
Odds Ratio 
Lower Upper 
PRA   0.002 3 1.000    
pra 20-39% 104.615 2737.293 0.001 1 0.970 2.71E45 0.000 . 
pra 40-79% 184.231 7782.417 0.001 1 0.981 1.02E80 0.000 . 
pra > 80% 336.529 8543.255 0.002 1 0.969 1.42E146 0.000 . 
Recipient Age 6.549 175.970 0.001 1 0.970 698.268 0.000 4.27E152 
AB match -540.569 15533.469 0.001 1 0.972 0.000 0.000 . 
Donor Female -148.864 4204.860 0.001 1 0.972 0.000 0.000 . 
Donor African 
American 
179.077 4649.711 0.001 1 0.969 5.92E77 0.000 . 
sCD30 -0.108 2.871 0.001 1 0.970 0.897 0.003 249.438 
MICA abs 
present 
-37.458 1643.244 0.001 1 0.982 0.000 0.000 . 
KIR inhibitory -313.185 8619.757 0.001 1 0.971 0.000 0.000 . 
MICA match 212.493 5609.826 0.001 1 0.970 1.93E92 0.000 . 
Constant -329.339 9187.545 0.001 1 0.971 0.000   
R

= 0.38(Cox & Snell), 1.00(Nagelkerke).  Model x(11) = 29.7, p = 0.002. * p < 0.05 
NOTE: B is the coefficient of the variable.  S.E. is the standard error of the coefficient.  
Wald is the Wald statistic value. d.f. is the degrees of freedom.  Sig. is the significance 
for the variable (p value). 
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